WO 2005/000794 PCT/FI2004/000387
PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS
Technical field
The present invention relates to therapeutically active compounds and
pharmaceutically acceptable salts and esters thereof useful in the treatment of nuclear
receptor, especially steroid receptor, and in particular androgen receptor (AR)
dependent conditions, and to pharmaceutical compositions containing such
compounds. In particular, the invention discloses novel non-steroidal propionanilide
structured compounds having utility as tissue-selective androgen receptor modulators
(SARM). The compounds of the invention, which possess AR agonist activity, are
useful in hormonal therapy, especially in treatment or prevention of conditions like
male hypogonadism and age-related conditions such as andropause.
Background of the invention
Nuclear hormone receptors make up a family of ligand-inducible trancription
factors whose members are involved in multiple physiological and developmental
functions. During the last 20 years, more than sixty structurally and functionally
related proteins belonging to this family have been identified. Nuclear hormone
receptor family includes, in addition to classical steroid receptors (estrogen receptor,
progesterone receptor, androgen receptor, glucocorticoid receptor and mineralo-
corticoid receptor) also receptors e.g. for thyroid hormone, vitamin D and retinoids.
Furthermore, a subclass of so-called orphan receptors for which no ligands have been
identified up to date belong to mis protein family. See Mangelsdorf et al, Cell (1995)
83(6): 835-839 and references therein. There exists an intense research directed to
identify novel modulators for these proteins, ultimate goal thus being to find new
therapies and treatment options for conditions and diseases modulated by
nuclear/steroid receptors.
Steroidal androgens have been used for decades in the treatment of diseases
resulting from deficiency in androgen action. They have also received attention for
their use as hormone replacement therapy of aging men and in regulation of male
fertility. However, current steroidal androgens, such as synthesized testosterone and
its derivatives, have severe limitations. Testosterone is rapidly degraded by the liver

WO 2005/000794 PCT/FI2004/000387
2
and thus has a low systemic bioavailability after oral administration. Further, orally
available testosterone formulations, e.g. methyltestosterone, have been associated
with alterations in liver function. Various other attempts have been made to
overcome these drawbacks of steroidal androgens as therapeutic agents, but with
limited success. Current testosterone formulations used in clinical practise include
e.g. injections, patches and gels.
In recent years, there has been growing interest in the development of
nonsteroidal modulators for steroid receptors for therapeutical use. It has been shown
that nonsteroidal ligands can achieve better receptor selectivity and better
physicochemical, pharmacokinetic and pharmacological properties. For androgen
receptor (AR), nonsteroidal antagonists (antiandrogens) are now used clinically to
counteract the undesirable actions of excessive androgens. In contrast, nonsteroidal
AR agonists, which would have potential in the treatment of diseases resulting from
androgen deficiency, have just recently been reported. Still, the structural elements of
nonsteroidal ligands that would lead to optimal agonist activity and tissue selectivity
are poorly defined.
Non-steroidal propionanilides having androgen receptor modulating activity
have been described e.g. in patent publications EP 100172, EP 253503, WO
98/53826 and WO 02/16310. The design of propionanilide structured AR modulators
has concentrated on compounds where the anilide ring is substituted by two electron-
withdrawing substituents such as halogen, cyano, trifluoromethyl or nitro, since such
substitution has been reported to enhance the androgen receptor binding affinity of
the ligand. See e.g. Tucker, H. et al., J. Med. Chem., 1988,31,954-959.
Summary of the invention
It has now been found that compounds of formula (I) are potent nuclear
receptor modulators, in particular androgen receptor modulators. Compounds of
formula (I) show remarkably high affinity and activity in androgen receptor and
possess utility as tissue-selective androgen receptor modulators (SARM).
Compounds of formula (I), which possess AR agonist activity, have been found to be
particularly suitable for use in hormonal therapy, especially in the treatment or
prevention of conditions like male hypogonadism and age-related conditions such as
andropause, e.g. for providing tissue-selective androgenic or anabolic effects. For

WO 2005/000794 PCT/F12004/000387
3
example, according to one preferred embodiment of the invention, the beneficial
androgenic effects are obtained without concurrent harmful stimulation of the
prostate. Compounds of the invention have generally also weak to moderate effect in
the progesterone receptor, particularly antagonistic effect. It is conceived that
concurrent progesterone antagonism may be beneficial as progesterone antagonism
has been demonstrated to improve glucose tolerance in certain animal models.
Compounds of the invention also provide good safety and sufficient water solubility.
The compounds of the present invention have a structure represented by
formula (I)

wherein
R1 is (C1-C7)alkyl, hydroxy(C1-C7)alkyl or-CCH2)n-CHO, wherein n is 0-6;
R2 is nitro, cyano or halogen;
R3 is hydrogen, (C1-C7)alkyl or halo(C1-C7)alkyl;
R4 is hydrogen, (C1-C7)alkyl, COR10 or SO2R13;
XisOorNH;
A is a group selected from:

wherein R5, R6 R7, Rg and R9 are independently hydrogen, halogen, nitro, cyano,
(C1-C7)alkyl, halo(C1-C7)alkyl, cyano(C1-C7)alkyl, amino, mono- or di(C1-C7)alkyl-
amino, amino(C1-C7)alkyl, hydroxy(C1-C7)alkyl, (CrC7)alkoxy(C1-C7)alkyl,
-NHCOR10, -N(COR10)2, -COR11 -OR12, -OSO2R13, -SO2R14, -NHSO2R13 or -SR15 or
an imide ring; or R5 and R5, R6 and R7, R7 and R8, or R8 and R9 form, together with any

WO 2005/000794 PCT/FI2004/000387
4
of the ring atom(s) to which they are attached, a condensed 5 to 7 membered aliphatic or
aromatic carbocyclic ring or a condensed 5 to 7 membered heterocyclic ring containing
1 to 3 heteroatom(s) selected from N, O and S;
R10 and Ru are independently (C1-C7)alkyl, (C2-C7)alkenyl, halo(C1-C7)alkyl,
amino(C1-C7)alkyl, mono- or di(C1-C7)a!kylamino(C1-C7)alkyl, (C6-C10)aryl, -N(Ri6)2
or-ORn;
R12 and R15 are independently hydrogen, (C1-C7)alkyl, (C2-C7)alkenyl,
halo(C1-C7)alkyl, amino(C1-C7)alkyl, mono- or di(C1-C7)alkylamino(C1-C7)alkyl,
(C6-C10)aryl, -COR,8;
Ri3 and RH are independently (C1-C7)alkyl or (C2-C7)alkenyl, halo(Ci-
C7)alkylor(C6-C,0)aryl;
Ri6 and R\y are independently hydrogen, (C1-C7)alkyl, (C2-C7)alkenyl,
halo(C1-C7)alkyl, amino(C1-C7)alkyl or (C6-C10)aryl;
Ris is (C1-C7)alkyl, (C2-C7)alkenyl, halo(C1-C7)alkyl or (C6-C10)aryl;
R19 and R2o are independently hydrogen, halogen, (C1-C7)alkyl or (C2-
C7)alkenyl;
and wherein each aryl or ring residue defined above may be substituted;
and pharmaceutically acceptable salts and esters thereof.
In one class of preferred compounds are compounds of formula (Ib), wherein
R1, R2, R3, R4, R5, Re, R7, R8 and R9 are as defined above.

In another class of preferred compounds are compounds of formula (I) or (Ib),
wherein R1 is methyl or hydroxymethyl and R2 is nitro or cyano. In another class of
preferred compounds are compounds of formula (I) or (Ib) wherein R4 is hydrogen
and R3 is methyl. In another class of preferred compounds are compounds of formula
(I) or (Ib) wherein R5, R6 R7, R8 and R9 are independently hydrogen, halogen, nitro,
cyano, (C1-C7)alkyl, (C1-C7)alkoxy, halo(C1-C7)alkyl, hydroxy(C1-C7)alkyl or -

WO 2005/000794 PCT/FI2004/000387
5
NHCOR10, wherein R10 is (C1-C7)alkyl, halo(C1-C7)alkyl, hydroxy or (C1-C7)alkoxy.
Particularly preferred are compounds of formula (I) or (Ib) wherein at least one of R5,
R6, R7, R8 and R9 is a halogen, preferably fluorine. Most preferably at least two of R5,
R6, R7, Rs and R9 are selected from the group consisting of halogen, preferably
fluorine, cyano and acetamido. It is particularly preferred that R6 is halogen,
preferably fluorine.
The present invention provides further a method of hormonal therapy,
comprising administering to a subject in need thereof a therapeutically effective
amount of a compound of formula (I).
The present invention provides further a method for the treatment or
prevention of androgen receptor (AR) dependent conditions, comprising
administering to a subject in need thereof a therapeutically effective amount of a
compound of formula (I).
The present invention provides further a method the treatment or prevention
of androgen deficiency, comprising administering to a subject in need thereof a
therapeutically effective amount of a compound of formula (I).
The present invention provides further a method the treatment or prevention
of male hypogonadism and age-related conditions such as andropause, comprising
administering to a subject in need thereof a therapeutically effective amount of a
compound of formula (I).
The present invention also relates to a method of hormonal therapy, e.g. the
treatment or prevention of androgen deficiency, comprising oral administration of
compound of formula (I).
The present invention also provides a pharmaceutical composition comprising
a compound of formula (I) together with a pharmaceutically acceptable carrier.
Brief Description of the Drawings
FIG. 1 shows the androgenic and anabolic activity of a compound of the
invention in levaior ani -muscle, seminal vesicle and ventral prostate of immature
male Spraque Dawley rat.

WO 2005/000794 PCT/F12004/000387
6
Detailed description of the invention
The compounds of the invention can be prepared by a variety of synthetic
routes analogously to the methods known in the literature using suitable starting
materials. In particular, the compounds of the invention can be prepared analogously
to the general methods described in WO 98/53826. For example, the compounds of
the invention can be prepared e.g. analogously or according to the reaction Scheme 1
or 2:
Scheme 1 (Method A)


WO 2005/000794 PCT/FI2004/000387
7


WO 2005/000794 PCT/FI2004/000387
8
Compounds of formula (I), wherein group A is a pyridine ring or derivative
thereof, can be prepared similarly as shown in Scheme 1 or 2 using suitable hydroxyl
pyridine derivative in the last step. Compounds of formula (I), wherein X is -NH,
can be prepared similarly as shown in Scheme 1 or 2 using suitable aniline derivative
in the last step.
Pharmaceutically acceptable salts, e.g. acid addition salts with both organic
and inorganic acids are well known in the field of Pharmaceuticals. Non-limiting
examples of these salts include chlorides, bromides, sulfates, nitrates, phosphates,
sulfonates, formates, tartrates, maleates, citrates, benzoates, salicylates and
ascorbates. Pharmaceutically acceptable esters, when applicable, may be prepared by
known methods using pharmaceutically acceptable acids that are conventional in the
field of Pharmaceuticals and that retain the pharmacological properties of the tree
form. Non-limiting examples of these esters include esters of aliphatic or aromatic
alcohols, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, .sec-butyl, terf-butyl
esters. Phosphate esters and carbonate esters, are also within the scope of the
invention.
The terms employed herein have the following meanings:
The term "halo" or "halogen", as employed herein as such or as part of
another group, refers to chlorine, bromine, fluorine or iodine.
The term "(C1-C7)alkyl", as employed herein as such or as part of another
group, refers to a straight, branched or cyclized chain radical having 1 to 7 carbon
atoms. Representative examples of (d-C7)alkyl include, but are not limited to,
methyl, ethyl, n-propyl, isopropyl, »-butyl, isobutyl, sec-butyl, terf-butyl, w-pentyl,
isopentyl, neopentyl, n-hexyl, cyclopentyl, cyclohexyl and the like.
The term "(C2-C7)alkenyl", as employed herein as such or as part of another
group, refers to a straight, branched or cyclized chain radical having 2 to 7 carbon
atoms, and containing (a) double bond(s).
The term "hydroxy", as employed herein as such or as part of another group,
refers to an -OH group.

WO 2005/000794 PCT/F12004/000387
9
The term "hydroxy(C1-C7)alkyl", as employed herein, refers to at least one
hydroxy group, as defined herein, appended to the parent molecular moiety through
an (C1-C7)alkyl group, as defined herein. Representative examples of hydroxy(Ci-
C7)alkyl include, but are not limited to, hydroxymethyl, 2,2-dihydroxyethyl, 1-
hydroxyethyl, 3-hydroxypropyl, 1-hydroxypropyl, 1-methyl-1-hydroxyethyl, 1-
methyl-1-hydroxypropyl, and the like.
The term "halo(C1-C7)alkyl", as employed herein, refers to at least one
halogen, as defined herein, appended to the parent molecular moiety through an (d-
C7)alkyl group, as defined herein. Representative examples of halo(C1-C7)alkyl
include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-
chloroethyl, 3-bromopropyl, and the like.
The term "cyano", as employed herein as such or as part of another group,
refers to a -CN group.
The term "cyano(C1-C7)alkyl", as employed herein, refers to a cyano group, as
defined herein, appended to the parent molecular moiety through an (C1-C7)alkyl
group, as defined herein. Representative examples of cyano(C1-C7)alkyl include, but
are not limited to, cyanomethyl, 1-cyanoethyl, 1-cyanopropyl, 2-cyanopropyl, and the
like.
The term "amino", as employed herein as such or as part of another group,
refers to a -NH2 group.
The term "amino(C1-C7)alkyl", as employed herein, refers to at least one
amino group, as defined herein, appended to the parent molecular moiety through an
(C1-C7)alkyl group, as defined herein. Representative examples of amino(C1-C7)alkyl
include, but are not limited to, aminomethyl, 2-aminoethyl, 1-aminoethyl, 2,2-
diaminoethyl, 3-aminopropyl, 2-aminopropyl, 4-aminobutyl, 1-methyl-1-aminoethyl,
and the like.
The term "mono- or di(C1-C7)alkylamino", as employed herein as such or as
part of another group, refers to one or two (C1-C7)alkyl group(s), as defined herein,
appended to the parent molecular moiety through an amino group, as defined herein.
Representative examples of mono-, or di(C]-C7)alkylamino include, but are not

WO 2005/000794 PCT/F12004/000387
10
limited to methylamino, ethylamino, propylamino, butylamino, dimethylamino,
diethylamino, ,/V-ethyl-N-methylamino, and the like.
The term "mono- or di(C1-C7)alkylamino(C1-C7)alkyr', as employed herein,
refers to a mono- or di(C1-C7)alkylamino group, as defined herein, appended to the
parent molecular moiety through a (C1-C7)alkyl group, as defined herein.
Representative examples of mono- or di(C1-C7)alkylamino(C1-C7)alkyl include, but
are not limited to, A-(V-dimethylaminomethyl, A/-(V-diethylaminomethyl, N-
methylaminoethyl, AT-methylaminopropyl, i-(-ethyl--(-methylaminomethyl, and the
like.
The term "(C1-C7)alkoxy", as employed herein as such or as part of another
group, refers to -O-(C1-C7)alkyl, wherein -(C1-C7)alkyl is as defined herein.
Representative examples of (C1-C7)alkoxy include, but are not limited to methoxy,
ethoxy, propoxy, butoxy, isobutoxy, sec-butoxy, ferf-butoxy, and the like.
The term "(C1-C7)alkoxy(C1-C7)alkyr, as employed herein, refers to at least
one (C1-C7)alkoxy group, as defined herein, appended to the parent molecular moiety
through an (C1-C7)alkyl group, as defined herein. Representative examples of (Ci-
C7)alkoxy(C1-C7)alkyl include, but are not limited to methoxymethyl, ethoxymethyl,
2-methoxyethyl, 2-ethoxyethyl, 3,3-dimethoxypropyl, 2,4-dimethoxybutyl and the
like.
The term "(C6-C10)aryl" as employed herein by itself or as part of another
group refers to a monocyclic or bicyclic group containing 6 to 10 carbon atoms in the
ring portion. Representative examples of (Q-CitOaryl include, but are not limited to
phenyl, naphtyl and the like.
The term "(C2-C7)acyr as employed herein by itself or as part of another
group refers to alkylcarbonyl or alkenylcarbonyl group having 2 to 7 carbon atoms,
and examples thereof include acetyl, propanoyl, isopropanoyl, butanoyl, sec-
butanoyl, fert-butanoyl and pentanoyl.
The term "substituted" as used herein in connection with various residues
refers to halogen substituents, such as fluorine, chlorine, bromine, iodine, or (Q-

WO 2005/000794 PCT/FI2004/000387
11
C7)alkyl, halo(C1-C7)alkyl, hydroxy, amino, (CrC7)alkoxy, (C2-C7)acyl (Cr
C7)alkylamino, amino(C1-C7)alkyl, nitro, cyano, or thiol substituents.
The "substituted" groups may contain 1 to 3, preferably 1 or 2, most
preferably 1 of the above mentioned substituents.
The definition of formula (I) above is inclusive of all the possible stereo-
isomers of the compounds, including geometric isomers, e.g. Z and E isomers (as
and trans isomers), and optical isomers, e.g. diastereomers and enantiomers, and all
prodrugesters, e.g. phosphate esters and carbonate esters. Furthermore, the invention
includes in its scope both the individual isomers and any mixtures thereof, e.g.
racemic mixtures. The individual isomers may be obtained using the corresponding
isomeric forms of the starting material or they may be separated after the preparation
of the end compound according to conventional separation methods. For the
separation of optical isomers, e.g. enantiomers, from the mixture thereof the
conventional resolution methods, e.g. fractional crystallisation, may be used.
Examples of preferred compounds of formula (I) include
3K4-Acetylaniino-3-fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide;
(2S)-3-(4-Acetylammo-3-fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide;
3-(4-Acetylammophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide;
(2S)-3-4-Acetylaminophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide;
3-3-CWoro-(fluorophenoxy)-2-hyd-(xy-2-memyl-N-(3-methyl-4-nitro-
phenyl)propionamide;
3-(4-Cyanophenoxy)-2-hydroxy-2-methyl-N-(3-mefliyl-4-nitrophenyl)-
propionamide;
3-(2-nuorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-mtrophenyl)-
propionamide;
3-(3-Ruorophenoxy)-2-hydroxy-2-metoyl-N-(3-methyl-4-nitrophenyl)-
propionamide;
3-(3-CMoro-(fluorophenoxy)-2-hydroxy-2-memyl-N-(3-methyl-4-nitro-
phenyl)propionamide;

WO 2005/000794 PCT/FI2004/000387
12
3-(3,4-Difluorophenoxy)-2-hydroxy-2-methyl-N-(3-meth)-d-4-nitrophenyl)-
propionamide;
3-(4-Chlorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide;
2-Hydroxy-3-(4-methoxyphenoxy)-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide;
3-(2,4-Dichloro-3,5-dimethylphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)-propionamide;
3-(4-CMoro-3-nitrophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide;
3-(4-Cyano-3-fluoro-phenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-iiitro-
phenyl)propionamide;
3-(4-Fluorophenylamino)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide;
3-[4-(3-Chloropropyl)phenoxy]-2-hydioxy-2-meihyl-N-(3-methyl-4-nitro-
phenyl)propionamide;
2-Hydroxy-3-(4-methoxymethylphenoxy)-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide;
2-Hydroxy-2-methyl-N-(3-methyl-(nitrophenyl)-3-(yridin-4-yloxo)propion-
amide;
3-[4-(2-CMoroethoxy)phenoxy]-2-hydioxy-2-methyl-N-(3-methyl-4-iiitro-
phenyl)-propionamide;
{2-Huoro-([2-hydroxy-2-(3-methyl-(mtrophenylcaibamoyl)propoxy]-
phenyljcarbamic acid ethyl ester;
3-44Z!yanophenylamino)-2-hydroxy-2-methyl-N-(3-me1hyl-(iutrophenyl-(
propionamide;
(2S)-3-(4-(-(mo-3-fluoro-phenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)-propionamide;
3-(3-CUoro-4K-(anophenylamino)-2-hydroxy-2-metiiyl-N-(3-methyl-4-
nitrophenyl)propioiiainide;
3-[4-(2-Bromodhyl)phenoxy]-2-hydroxy-2-metliyl-N-(3-mefliyl-4-nitro-
phenyl)propionamide;
3-4--(ino-3-fluorophenoxy)-N-(3-ethyl-(nitrophenyl)-2-hydroxy-2-methyl-(
propionamide; and
3-(3-(-(oro-4-(yanophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide.

WO 2005/000794 PCT/FI2004/000387
13
Compounds of the invention maybe administered to a patient in
therapeutically effective amounts which range usually from about 0.1 to about 1000
mg per day depending on the age, weight, ethnic group, condition of the patient,
condition to be treated, administration route and the androgen (AR) modulator used.
The compounds of the invention can be formulated into dosage forms using the
principles known in the art It can be given to a patient as such or in combination
with suitable pharmaceutical excipients in the form of tablets, granules, capsules,
suppositories, emulsions, suspensions or solutions. Choosing suitable ingredients for
the composition is a routine for those of ordinary skill in the art. It is evident that
suitable carriers, solvents, gel forming ingredients, dispersion forming ingredients,
antioxidants, colours, sweeteners, wetting compounds and other ingredients normally
used in this field of technology may be also used. The compositions containing the
active compound can be given enterally or parenterally, the oral route being the
preferred way. The contents of the active compound in the composition is from about
0.5 to 100 %, preferably from about 0.5 to about 20 %, per weight of the total
composition.
The present invention will be explained in more detail by the following
examples. The examples are meant only for illustrating purposes and do not limit the
scope of the invention denned in claims.
EXPERIMENTS
Experiment 1. AR Binding Assay
Ventral prostates were obtained form rats castrated 24 h prior to sacrifice.
Fresh prostate was minced and washed with Buffer A (Schilling and Iiao, Prostate,
5:581-588,1984). The minces were then homogenized in 3 x volume of Buffer A
containing protease inhibitors (Complete, Mini, EDTA-free Roche). The homogenate
was centrifuged at 30000g for 30 min. The resultant supematants were treated with 1
x volume of dextran-coated charcoal solution (12,5 g activated charcoal, 12,5 g
dextran per liter of buffer A) to remove endogenous steroids. The samples were
incubated for 5 min and centrifuged at 16000g for 10 min. Aliquots of the charcoal-
treated cytosol were taken for androgen receptor assays. All procedures were carried
out at 0-4°C.

WO 2005/000794 PCT/FI2004/000387
14
Cytosol androgen receptor concentration was determined as described
(Isomaa et al., Endocrinology, 111: 833-843,1982) with minor modifications.
Cytosol preparations were prepared as described above, and bound and free steroids
were separated by treatment with an equal volume of dextran-charcoal suspension for
5 min at 4°C followed by centrifugation at 16000g for 10 min. Bound radioactivity
was determined by counting supernatant fractions in 1 ml of OptiPhase HiSafe3 or
OptiPhase Supermix (PerkinEhner).
Cytosol preparations were labelled with 1 nM [3H]-mibolerone overnight at
0°C (total). To determine AR binding activity of the compounds of the present
invention (test compounds), the ability of test compounds to compete with
[-(7a,i7a-dimethyl-17p-hydroxy-4-estren-3-one ([3H]-mibolerone) binding was
studied. 1 nM [3H]-mibolerone and test compounds in two concentrations (0,2 and 2
uM) were incubated overnight at 0°C. To determine non-specific binding, parallel
incubations were carried out using 1 nM concentration [-(-mibolerone with 500-
fold molar excess of unlabelled testosterone. Two to four replicates were used for
each sample. After incubation, bound and free steroids were separated as described
above and bound radioactivity was determined. The ability of the test compounds to
bind AR is reported as reduction in bound radioactivity obtained with 1 nM [3H]-
mibolerone. The results are shown in Table 1. The results (% inhibition) were
calculated as: % inhibition = 100 - (100x(averagetestcampound/a.veragetota]))-
Table 1. AR binding assay. Inhibition (%) of [3H]-mibolerone binding.

Compound ofExample No. Inhibition (%) of [3H]-miboleronebinding at 0.2 uM Inhibition (%) of [3H]-miboleronebinding at2.0uM
1. 91 101
2. 93 100
3. 103 115
4. 90 88
5. 25 74
6. 68 95
7. 74 98
8. 93 109
9. 41 102
10. 5 83

WO 2005/000794 PCT/FI2004/000387
15

11. 98 105
12. 77 101
13. 77 90
14. 75 95
15. 46 77
16. 50 91
17. 95 98
18. 90 99
19. 83 99
20. 13 83
21. 26 91
23. 88 92
24. 75 93
25. 96 98
26. 62 92
27. 34 89
28. 90 88
29. 92 90
30. 80 99
31. 18 75
36. 3 50
42. 83 97
43. 95 99
44. 83 100
50. 96 99
51. 73 92
52. 90 115
55. 87 99
56. 90 95
58. 84 93
63. 92 98
64. 79 89
66. 69 93
79. 89 98
80. 87 99
81. 85 98
Experiment 2. AR agonism and antagonism in immature male rats
The title compound of Example 3, abbreviated here as compound A, was
further studied in in vivo experiment. The agonism and antagonism of the compound

WO 2005/000794 PCT/FI2004/000387
16
with subcutaneous dosing was tested in immature male Spraque Dawley rat 3-day
assay by analyzing the relative weights of ventral prostate, seminal vesicle, and
levator ani-muscle. Testosterone propionate was used as a reference compound.
Testosterone propionate (abbreviated here TP) and compound A were first
dissolved into DMSO and then into the vehicle sesame oil. Sprague-Dawley
untreated male rats (18-19 days old) weighing about 50 g were used in the
experiment. Rats were weighed and randomly distributed into five groups, with 5
animals per group (Table 1). Compound A (doses 2 and 20 mg/kg) and testosterone
propionate (dose 5 mg/kg) were given subcutaneously (s.c.) into the neck/back of the
animals at a constant volume of 100 microl dosing solution/animal/day. The animals
were dosed once daily for three days, and clinical signs were recorded during dosing.
At the end of the study, animals were weighed and anaesthetised by CO2
asphyxiation. Ventral prostate, seminal vesicles, and levator ani-muscle were
dissected out, chilled, and weighed. For statistical analysis, the weights of all organs
were normalized to body weights, and analyzed for statistical significant difference
by single-factor ANOVA.
Table 2. Animal groups and experimental design

Dose group & group number Number of animals
1. Vehicle 5
2. Testosterone propionate (TP) 5mg/kg s.c. 5
3. Compound A, 2 mg/kg 5
4. Compound A, 20 mg/kg 5
5. TP 5 mg/kg + Compound A, 20 mg/kg s.c. 5
The results are shown in Figure 1. Compound A shows androgenic and
anabolic activity. The relative weights of ventral prostate, seminal vesicle and levator
ani -muscle increased significantly with administration of testosterone propionate.
Compared with testosterone propionate, compound A showed tissue selectivity. At
dose 20 mg/kg it clearly increased the relative weight of levator ani-muscle and
significantly the relative weight of seminal vesicle, but only minimally the relative
weight of the prostate. Furthermore, compound A showed significant antagonistic
activity in seminal vesicle. Neither testosterone propionate nor compound A had any
effect on the body weights (data not shown). In the Figure, "a" means agonism,

WO 2005/000794 PCT/FI2004/000387
17
p-0.01 compared to vehicle group, "b" means antagonism, p-0.05 compared to
testosterone group, bars represent mean ± SEM.
EXAMPLES:
Example 1. (Method A)
3-(4-Awtylaminophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
a)2-Methyl-N-(3-methyl-4-nitrophenyl)acrylamide
3-Methyl-4-nitroaniUne (2.0 g, 13 mmol) in NJN-dimethylacetamide (DMAC)
(6 ml) was added dropwise to a cooled solution of methacryloyl chloride (2.0 ml,
20.7 mmol) in a nitrogen atmosphere while the temperature of the reaction mixture
was maintained between 0 -5 °C. The solution was allowed to warm to room
temperature and the mixture was stirred over night. The mixture was poured into
water (70 ml) and extracted with ethyl acetate (4 x 40 ml). The organic phase was
washed with saturated Na2CO3 (3 x 20 ml) and water (1 x 50 ml), dried over Na2SO4
and evaporated. The yield of the crude product was 4.17 g (contains DMA,
theoretical yield 2.9 g), and it was used without further purifications.1!! NMR
(DMSO-de): 1.97 (3H, s), 2.55 (3H, s), 5.62 (1H, m), 5.96 (1H, m), 7.80 (2H, m),
8.05 (1H, m), 10.22 (1H, s).
b) 2-Methyloxirane-2-carboxylic acid (3-methyl-4-nitrophenyl)amide
m-Chloroperoxybenzoic acid (6.7 g, 29.9 mmol) was added in portions at 60
°C to a solution of 2-methyl-N-(3-methyl-4-nitrophenyl)acrylamide (2.9 g, 13.2
mmol) and 2,6-di-tert-butyl-4-methylphenol (66 mg) in 1,2-dichloroethane (80 ml).
The stirring was continued at 60 °C for 6 h, and the reaction mixture was allowed to
cool to room temperature. The precipitated m-chlorobenzoic acid was filtered, and
the filtrate was extracted with 1 M Na2CC)-3 (4 x 60 ml). The organic phase was dried
over Na2SO4 and evaporated. The yield was 3.05 g. ]H NMR (DMSO-d-;): 1.54 (3H,
s), 2.51 (3H, s), 2.99 (1H, d, J=5.1 Hz), 3.05 (1H, d, J=5.1 Hz), 7.79 (2H, m), 8.01
(lH,m),9.98(lH,s).

WO 2005/000794 PCT/FI2004/000387
18
(c)3-(4-Acetylaminophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitiophenyl)propionamide
A solution of 4-acetajnidophenol (2.9 g, 19 mmol) in THF (60 ml) was added
dropwise to a stirred suspension of sodium hydride (0.46 g, 19 mmol, 60 %
dispersion in mineral oil) in THF (60 ml) and the temperature was kept below 5 °C
during the addition. The mixture was stirred for 10 min and a solution of 2-methyl-
oxirane-2-carboxylic acid (3-methyl-4-nitrophenyl)amide (3.05 g, 13 mmol) in THF
(120 ml) was added. The mixture was heated to 60 °C and stirred at mis temperature
for 7 h, and allowed to cool to the room temperature. The solvent was evaporated and
the residue was dissolved to the mixture of water (ISO ml) and ethyl acetate (ISO ml).
The pH was adjusted to 2 - 3 with 2 M HC1 and the phases were separated. The
aqueous phase was extracted with ethyl acetate (4 x 150 ml). The combined organic
phase was washed with 1 M Na2CC)-3 (5 x 100 ml), dried over Na2SO4 and
evaporated. The oily residue was crystallised from the mixture of ethyl acetate -
diethyl ether (10 :1). The crude product was recrystallised from ethyl acetate. The
yield was 2.5 g. *H NMR (DMSO-de): 1.42 (3H, s), 1.99 (3H, s), 2.53 (3H, s), 3.93
(1H, d, J=9.6 Hz), 4.16 (1H, d, J=9.6 Hz), 6.20 (1H, bs), 6.84 (2H, d, J=9.0 Hz), 7.44
(2H, d, J=9.0 Hz), 7.88 (1H, dd, J=9.0 Hz and 2.3 Hz), 7.93 (1H, d, J=2.3 Hz), 8.04
(1H, d, J=9.0 Hz), 9.76 (1H, s), 10.15 (1H, bs).
Example 2.
3-(4-Acetylanmio-3-fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
a) N-(2-Fluoro-4-hydroxyphenyl)acetaniide
Acetic anhydride (1.3 ml, 13.8 mmol) was added dropwise to a solution of 4-
amino-3-fluorophenol (1.0 g, 7.9 mmol) in acetic acid (25 ml) at room temperature.
The reaction mixture was stirred at room temperature for 2 h and water (2 ml) was
added and the stirring was continued for 30 minutes at room temperature. The
mixture was evaporated to dryness in vacuo. The yield of the crude product was 1.3 g
(100 %) and it was used without further purification.
*H NMR (DMSO-d6): 2.00 (3H, s), 6.50-6.68 (2H, m), 7.39 (1H, m), 9.39
(1H,S),9.72(1H,S).

WO 2005/000794 PCT/FI2004/000387
19
b)3-(4-Acetylamino-3-fluorophenoxy)-2-hydroxy-2-methyl-N-(3-niethyl-4-
nitrophenyl)propioiuanide
The compound was synthesised according to the procedure described in
Example lc. N-(2-Fluoro-4-hydroxyphenyl)acetamide (0.5 g, 3.0 mmol) and 2-
methyloxirane-2-carboxylic acid (3-methyl-4-nitrophenyl)amide (0.6 g, 2.5 mmol)
was used as starting materials. The product was crystallised from the mixture of ethyl
acetate and diethyl ether (1:1). The yield was 0.39 g. *H NMR (DMSO-de): 1.42 (3H,
s), 2.02 (3H, s), 2.53 (3H, s), 3.97 (1H, d, J=9.7 Hz), 4.21 (1H, d, J=9.7 Hz), 6.23
(1H, bs), 6.72 (1H, m), 6.90 (1H, m), 7.56 (1H, m), 7.88 (1H, dd, J=9.0 Hz and 2.2
Hz), 7.93 (1H, d, J=2.2 Hz), 8.03 (1H, d, J=9.0 Hz), 9.51 (1H, s), 10.15 (1H, bs).
Example 3. (Method B)
(2S)-3-(4-Acetylaminophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
a) (2R)-l-(2-Me1hylacryloyl)pyrrolidine-2-carboxylic acid
D-proline (5 g, 43.4 mmol) was dissolved in 2 M NaOH (26 ml) and cooled in
an ice bath, and the solution was diluted with acetone (26 ml). An acetone solution
(26 ml) of methacryloyl chloride (6.3 ml, 65.1 mmol) and a 2 M NaOH solution (34
ml) were simultaneously added over a period of lh to the solution of D-proline. After
addition the resulting mixture was stirred for 3 h at room temperature. The mixture
was evaporated at 40 °C, extracted with ether (2 x 40 ml) and acidified to pH 2 with
concentrated HC1. The resulting mixture was extracted with ethyl acetate (3 x 50 ml),
dried over Na2SO4 and evaporated. The yield was 11.5 g (theoretical 8.0 g), and it
was used without further purifications.
b)(3R,8aR)-3-Bromomethyl-3-memyltetrahydropyrrolo[2,l-c][l,4]oxazine-
1,4-dione
NBS (16 g, 89.9 mmol) was dissolved in DMF (50 ml) and added at room
temperature to a solution of (2R)-l-(2-methylacryloyl)pyrrolidine-2-carboxylic acid
(11.5 g, contains 8.0 g of the corresponding starting material, 43.4 mmol) in DMF
(50 ml). The mixture was stirred for 20 h and evaporated at 80-90 °C. The residue
was mixed with water (250 ml) and extracted with ethyl acetate (4 x 80ml). The

WO 2005/000794 PCT/FI2004/000387
20
combined ethyl acetate phases were washed with 1 M NaHCO3 solution (2 x 50 ml)
and water (1 x SO ml). The organic phase was dried over Na2SO4 and evaporated.
The yield of the crude oil was 9.3 g. Ethyl acetate (10 ml) was added and the mixture
was stirred in an ice bam. The precipitated product was filtered and washed with
cooled ethyl acetate. The yield was 1.2 g. 'H NMR (DMSO-de): 1.58 (3H, s), 1.75-
2.10 (3H, m), 2.25 (1H, m), 3.30-3.55 (2H, m), 3.87 (1H, d, J=l 1.4 Hz), 4.03 (1H, d,
J=11.4Hz),4.70(lH,m).
c) (2R)-3-Bromo-2-hydroxy-2-methylpropionic acid
(3R,8aR)-3-Bromomemyl-3-memyltetrahydropyrrolo[2,l-c][l,4]oxazine-l,4-
dione (1.1 g, 4.2 mmol) was dissolved in concentrated HC1 (10 ml) and refluxed for 7
h. The mixture was cooled to room temperature. Water (20 ml) was added and the
mixture was extracted with ethyl acetate (3 x 20 ml). The combined organic phase
was evaporated and the residue was mixed with toluene (5 ml). The crystallised
product was filtered and washed with toluene. The yield was 0.74 g. *H NMR
(DMSO-de): 1.37 (3H, s), 3.54 (1H, d, J=10.2 Hz), 3.64 (1H, d, J=10.2 Hz), 5.35
(1H, bs), 12.80 (1H, bs).
d)(2R)-3-Bromo-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
Thionyl chloride (0.48 ml, 6.6 mmol) was added dropwice to a solution of
(2R)-3-Bromo-2-hydroxy-2-methylpropionic acid (1.0 g, 5.5 mmol) in 10 ml of
DMA at -5 to -10 °C. The mixture was stirred for 2 h, and a solution of 3-methyl-4-
nitroaniline (0.83 g, 5.5 mmol) in 7 ml of DMA was added to the above mixture. The
resulting mixture was stirred for 3 h at room temperature and poured into water (250
ml). The aqueous phase was extracted with ethyl acetate (4 x 50 ml), dried over
Na2SO4 and evaporated. The yield of the desired compound was 2.5 g (contains also
DMA), and it was used without further purifications. lH NMR (DMSO-de): 1.48 (3H,
s), 2.53 (3H, s), 3.58 (1H, d, J=10.4 Hz), 3.82 (1H, d, J=10.4 Hz), 6.34 (1H, bs), 7.86
(1H, dd, J=9.0 Hz and 12 Hz), 7.91 (1H, d, J=2.2 Hz), 8.04 (1H, d, J=9.0 Hz), 10.09
(lH,bs).
e)(2S)-3-(4-Acetylaminophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide

WO 2005/000794 PCT/FI2004/000387
21
A solution of 4-acetamidophenol 0.62 g, 4.1 mmol) in THF (7 ml) was added
dropwise to a stirred suspension of sodium hydride (0.27 g, 6.8 mmol, 60 %
dispersion in mineral oil) in THF (6 ml) and the temperature was kept below 5 °C
during the addition. The mixture was stirred for 10 min and a solution of (2R)-3-
bromo-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)propionamide (0.86 g, 2.7
mmol) in THF (7 ml) was added. The mixture was stirred at room temperature for 30
min and then at 60 °C for 5 h, and allowed to cool to the room temperature. The
solvent was evaporated and the residue was dissolved to the mixture of water (80 ml)
and ethyl acetate (80 ml). The pH was adjusted to 2 - 3 with 2 M HC1 and the phases
were separated. The organic phase was washed with 1 M Na2CC)-3 (6 x 30 ml), dried
over Na-(SO4 and evaporated. The oily residue was crystallised from ethyl acetate.
The yield was 0.27 g. !H NMR (DMSO-d6): 1.42 (3H, s), 1.99 (3H, s), 2.53 (3H, s),
3.93 (1H, d, J=9.6 Hz), 4.16 (1H, d, J=9.6 Hz), 6.20 (1H, bs), 6.84 (2H, d, J=9.0 Hz),
7.44 (2H, d, J=9.0 Hz), 7.88 (1H, dd, J=9.0 Hz and 2.3 Hz), 7.93 (1H, d, J=2.3 Hz),
8.04 (1H, d, J=9.0 Hz), 9.76 (1H, s), 10.15 (1H, bs).
Example 4.
(2S)-3-(4-Acetylamino-3-fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
(2S)-3-(4-Awtylammo-3-fluorc-(henoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide was prepared according to the method B as described in
Example 3e starting from 4-acetylamino-3-fluorophenol and N-[3-methyl-4-
(nitro)phenyl]-(2R)-3-bromo-2-hydroxy-2-methylpropanainide. *HNMR (DMSO-
de): 1.42 (3H, s), 2.02 (3H, s), 2.53 (3H, s), 3.97 (1H, d, J=9.7 Hz), 4.21 (1H, d,
J=9.7 Hz), 6.23 (1H, bs), 6.72 (1H, m), 6.90 (1H, m), 7.56 (1H, m), 7.88 (1H, dd,
J=9.0 Hz and 2.2 Hz), 7.93 (1H, d, J=2.2 Hz), 8.03 (1H, d, J=9.0 Hz), 9.51 (1H, s),
10.15 (1H, bs).
Example 5.
4-[2-Hyb-(xy-2-(3-memyl-(-mtrophenylcarbamoyl)propoxy]benzamide
4-[2-Hydroxy-2-(3-memyl-(nitrophenylcarbamoyl)propoxy]benzamidewas
prepared as described in Example 1 starting from 4-hydroxybenzamide and 1-(2-
epoxy-2-methyl-N-(3-methyl-4-nitrophenyl)-2-propananiide. 'H NMR (400 MHz,

WO 2005/000794 PCT/FI2004/000387
22
DMSO-de): 1.45 (3H, s), 2.53 (3H, s), 4.04 (1H, d, J = 9.7 Hz), 4.28 (1H, d, J = 9.7
Hz), 6.26 (1H, s), 6.94-6.98 (2H, m), 7.19 (1 H, br s), 7.80-7.83 (3H, m), 7.89 (1H,
dd, J = 9.0 Hz, J = 2.2 Hz), 7.95 (1H, d, J = 2.0 Hz), 8.05 (1H, d, J = 9.0 Hz), 10.19
(1H, s).
Example 6.
3-(3,4-Dichlorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(3,4-IMchlorophenoxy)-2-hydroxy-2-methyl-N-(3-metfayl-4-nitrophaiyl)-
propionamide was prepared as described in Example 1 starting from 3,4-dichloro-
phenol and l,2-epoxy-2-methyl-N-(3-methyl-4-nitrophenyl)-2-propananiide.
•H NMR (400 MHz, DMSO-de): 1.43 (3H, s), 2.53 (3H, s), 4.02 (1H, d, J = 9.9 Hz),
4.28 (1H, d, J = 9.9 Hz), 6.27 (1H, s), 6.95 (1H, dd, J = 8,9 Hz, J = 2,8 Hz), 7.25 (1
H, d, J = 2,8 Hz), 7.49 (1 H, d, J = 8,9 Hz), 7.88 (1H, dd, J = 9.0 Hz, J = 2.3 Hz),
7.93 (1H, d, J = 2.0 Hz), 8.04 (1H, d, J - 9.0 Hz), 10.17 (1H, s).
Example 7.
4-[2-Hydroxy-2-(3-methyl-4-nitrophenylcarbamoyl)propoxy]benzoicacid
ethyl ester
4-[2-Hydroxy-2-(3-methyl-4-nitiDphenylcarbamoyl)propoxy]benzoicacid
ethyl ester was prepared as described in Example 1 starting from ethyl 4-hydroxy-
benzoate and l-(-epoxy-2-methyl-N-(3-methyl-4-nitrophenyl)-2-propanamide.
JH NMR (400 MHz, DMSO-de): 1.30 (3H, t, J = 7.1 Hz), 1.45 (3H, s), 2.53 (3H, s),
4.07 (1H, d, J = 9.7 Hz), 4.26 (2H, q, J = 7.1 Hz), 4.30 (1H, d, J = 9.7 Hz), 6.29 (1H,
s), 7.01-7.05 (2H, m), 7.86-7.91 (3H, m), 7.94 (1H, d, J = 1.9 Hz), 8.04 (1H, d, J -
9.0 Hz), 10.20 (lH,s).
Example 8.
3-(3-;Uoro-4-fluorophOToxy)-2-hydroxy-2-memyl-N-(3-me1hyl-4-nitro-
phenyl)propionamide
3-(3-Chloro-4-fluorophenoxy)-2-hydroxy-2-methyl-N-3-methyl-4-mtro-
phenyl)propionamide was prepared as described in Example 1 starting from 3-chloro-
4-fluorophenol and l-(-epoxy-2-methyl-N-(3-methyl-4-nitrophenyl)-2-propananiide.

WO 2005/000794 PCT/FI2004/000387
23
'H NMR (400 MHz, DMSO-d6): 1.42 (3H, s), 2.53 (3H, s), 4.00 (1H, d, J = 9.8 Hz),
4.25 (1H, d, J = 9.8 Hz), 6.21 (1H, s), 6.89-6.95(lH, m), 7.15-7.19 (1 H, m), 7.26-
7.32 (1H, m), 7.87 (1H, dd, J = 8.9 Hz, J = 2.3 Hz), 7.91 (1H, d, J = 1.9 Hz), 8.03
(1H, d, J = 8.9 Hz), 10.12 (1H, s).
Example 9.
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(4-trifluoromethoxy-
phenoxy)propionainide
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(4-trifluoromethoxy-
phenoxy)propionamide was prepared as described in Example 1 starting from 4-
(trifluoromethoxy)phenol and l,2-epoxy-2-methyl-N-(3-methyl-4-nitrophenyl)-2-
propanamide. ]H NMR (400 MHz, DMSO-dg): 1.44 (3H, s), 2.53 (3H, s), 4.01 (1H,
d, J = 9.7 Hz), 4.24 (1H, d, J = 9.7 Hz), 6.24 (1H, s), 6.99-7.05(2H, m), 7.22-7.30 (2
H, m), 7.88 (1H, dd, J = 8.9 Hz, J = 2.3 Hz), 7.93 (1H, d, J - 1.9 Hz), 8.03 (1H, d, J =
8.9 Hz), 10.14 (lH,s).
Example 10.
3-(2,3-DicUorophenoxy)-2-hydroxy-2-me1hyl-N-(3-me1hyl-4-nitrq)henyl)-
propionamide
3-(2,3-Dichlorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-mtrophenyl)-
propionamide was prepared as described in Example 1 starting from 2,3-dichloro-
phenol and l,2-epoxy-2-methyl-N-(3-methyl-4-nitropb.enyi)-2-propanamide.
'H NMR (400 MHz, DMSO-de): 1.46 (3H, s), 2.53 (3H, s), 4.16 (1H, d, J = 9.8 Hz),
4.27 (1H, d, J « 9.8 Hz), 6-(7 (1H, s), 7.16-7.21(2H, m), 7.27-7.33 (1 H, m), 7.87
(1H, dd, J = 8.9 Hz, J = 2.3 Hz), 7.91 (1H, d, J = 1.9 Hz), 8.03 (1H, d, J = 8.9 Hz),
10.14 (1H, s)
Example 11.
3-(4-Fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(4-Fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example 1 starting from/7-fluorophenol
and l,2-epoxy-2-memyl-N-[3-methyl-4-nitrophenyl]-2-propanamide. *H NMR (400

WO 2005/000794 PCT/FI2004/000387
24
MHz, DMSO-de): 1.43 (3H, s), 2.53 (3H, s), 3.96 (1H, d, J= 9.6 Hz), 4.20 (1H, d, J
= 9.6 Hz), 6.21 (1H, s), 6.90-6.96 (2H, m), 7.06-7.12 (2H, m), 7.89 (1H, dd, J= 9.0
Hz, /= 2.2 Hz), 7.90 (1H, d, J= 1.9 Hz), 8.04 (1H, d, J= 9.0 Hz), 10.15 (1H, s).
Example 12.
2-H)droxy-2-methyl-N-(3-methyl-4-nitrophmyl)-3-/?-tolyloxypropionamide
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-/?-tolyloxypropi6iiaiiiide
was prepared as described in Example 1 starting fromjo-methylphenol and 1,2-
epoxy-2-methyl-N-[3-methyl-4-nitrophenyl]-2-propanamide. lH NMR (400 MHz,
DMSO-dfi): 1.43 (3H, s), 2.21 (3H, s), 2.53 (3H, s), 3.93 (1H, d,J= 9.6 Hz), 4.17
(1H, d, J= 9.5 Hz), 6.18 (1H, s), 8.53 (2H, d, /= 8.5 Hz), 7.06 (2H, d, J= 8.4 Hz),
7.89 (1H, dd, J= 2.2 Hz, J= 9.0 Hz), 7.94 (1H, d, J= 1.8 Hz), 8.04 (1H, d, J= 9.0
Hz), 10.14 (lH,s).
Example 13.
2-Hydroxy-2-methyl-N-(3-methyl-4-mtro-(
amino)phenoxy]propionamide
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-[4-(2-(-(-trifluoroacetyl-(
amino)phenoxy]propionamide was prepared as described in Example 1 starting from
/-(N-trifluoroacetamidophenol and 1-(2-epoxy-2-methyl-N-[3-methyl-4-nitroplienyl]-
2-propanamide. !H NMR (400 MHz, DMSO-de): 1.43 (3H, s), 2.53 (3H, s), 3.98
(1H, d, J= 9.6 Hz), 4.22 (1H, d, 7= 9.6 Hz), 6.22 (1H, s), 6.93-6.98 (2H, m), 7.52-
7.56 (2H, m), 7.88 (1H, dd, /= 9.0 Hz, 7= 2.2 Hz), 7.93 (1H, d, J= 1.9 Hz), 8.04
(lH,d, J=9.0 Hz).
Example 14.
2-Hydroxy-2-memyl-N-(3-methyl-(nitrophenyl)-3-phenoxypropioriamide
2-Hydroxy-2-methyl-N-(3-mc&yl-4-rdtrophenyl)-3-phenoxypi-(ionamide
was prepared as described in Example 1 starting from phenol and l,2-epoxy-2-
methyl-N-[3-methyl-4-nitrophenyl]-2-propanamide. !H NMR (400 MHz, DMSO-ds):
1.44 (3H, s), 2.53 (3H, s), 3.97 (1H, d, /= 9.6 Hz), 4.21 (1H, d, /= 9.6 Hz), 6.21
(1H, s), 6.90-6.95 (3H, m), 7.24-7.29 (2H, m), 7.89 (1H, dd, J= 2.3 Hz, J = 9.0 Hz),
7.94 (1H, d, /= 2.0 Hz), 8.04 (1H, d, V= 9.0 Hz), 10.16 (1H, s).

WO 2005/000794 PCT/FI2004/000387
25
Example 15.
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(4-trifluoroinethyl-
phenoxy)propionamide
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(4-trifluoromethyl-
phenoxy)propionamide was prepared as described in Example 1 starting fromp-
hydroxybenzotrifluoride and 2-methyloxirane-2-carbocylic acid (3-methyl-4-
nitrophenyl)amide. The crude product was purified by flash chromatography using
heptane/ethyl acetate (95:5) as eluent. Crystallization from toluene. 'H NMR (400
MHz, CDC13): 1.62 (3H, s), 2.65 (3H, s), 3.25 (1H, s, -OH), 4.05 (1H, d, 2Jzem = 9.1
Hz), 4.51 (1H, d, 2Jgem = 9.0 Hz), 7.00 (2H, d, 3J = 8.8 Hz), 7.57 (2H, d, 3J= 8.8 Hz),
7.58 (1H, dd, 3J= 8.9 Hz, V= 2.7 Hz), 7.66 (1H, d, V= 2.2 Hz), 8.08 (1H, d, V=
8.9 Hz), 8.9 (1H, broad s, -NHCO-).
Example 16.
3-(4-Acetylphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(4-Acetylphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example 1 starting from 4'-hydroxy-
acetophenone and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide.
The crude product was purified by flash chromatography using heptane/ethyl acetate
(95:5) as eluent. Crystallization from toluene, m.p. 153-155 °C. ]H NMR (400 MHz,
CDCI3): 1.62 (3H, s), 2.57 (3H, s), 2.65 (3H, s), 3.26 (1H, s, -OH), 4.07 (1H, d, 2Jgfan
- 9.1 Hz), 4.53 (1H, d, 2Jgem = 9.1 Hz), 6.96 (2H, d, 3J= 8.9 Hz), 7.58 (1H, dd, 3J=
8.9 Hz, 4J= 2.4 Hz), 7.66 (1H, d, 4J= 2.3 Hz), 7.94 (2H, d, V= 8.9 Hz), 8.09 (1H, d,
SJ- 9.0 Hz), 8.95 (1H, broad s, -NHCO-).
Example 17.
3-(4-Cyanophenoxy)-2-hydroxy-2-methyl-N-(3-metiiyl-4-nitrophenyl)-
propionamide
3-(4-Cyanophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example 1 starting from 4-cyanophenol
and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide. The crude

WO 2005/000794 PCT/FI2004/000387
26
product was purified by flash chromatography using heptane/ethyl acetate as a
gradient eluent. Crystallization from toluene. ]H NMR (400 MHz, DMSO-d6)-1.44
(3H, s), 2.53 (3H, s), 4.08 (1H, d, 2Jztm = 9.8 Hz), 4.33 (1H, d, 2J&m = 9.9 Hz), about
6.3 (1H, broad s, -OH), 7.10 (2H, d, 3J= 8.8 Hz), 7.75 (2H, d, V= 8.8 Hz), 7.88 (1H,
dd, 3J= 9.0 Hz, V= 2.3 Hz), 7.93 (1H, d, 4J= 2.0 Hz), 8.04 (1H, d, 3J= 9.0 Hz),
about 10.2 (1H, broad s, -NHCO).
Example 18.
3-(3-Fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(3-Ruorophenoxy)-2-hydroxy-2-niethyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example 1 starting from 3-fluorophenol
and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide. The crude
product was purified by flash chromatography using heptane/ethyl acetate as a
gradient eluent Crystallization from toluene/heptane, m.p. 83-86 °C. *H NMR (400
MHz, DMSO-40:1.43 (3H, s), 2.53 (3H, s), 3.99 (1H, d, 2Jtim = 9.7 Hz), 4.24 (1H,
d, 2Jgem = 9.7 Hz), 6.26 (1H, broad s, -OH), 6.73-7.78 (2H, m), 6.81 (1H, m), 7.28
(1H, m), 7.89 (1H, dd, 3J= 9.0 Hz, 4J= 2.3 Hz), 7.94 (1H, d, V« 2.0 Hz), 8.04 (1H,
d, V» 8.9 Hz), 10.17 (1H, broad s, -NHCO-).
Example 19.
3-(2-Fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(2-nuorophenoxy)-2-hydroxy-2-memyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example 1 starting from 2-fluorophenol
and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide. The crude
product was purified by flash chromatography using heptane/ethyl acetate (90:10) as
eluent. Crystallization from ethyl acetate/heptane, m.p. 94-96 °C. *H NMR (400
MHz, DMSO-dtf): 1.44 (3H, s), 2.53 (3H, s), 4.07 (1H, d, 2JiVH = 9.8 Hz), 4.27 (1H,
*,2Jgm = 9.8Hz),6.27(1H,broads,-OH),6.93 (1H,m),7.10(1H,m),7.14-7.21
(2H, m), 7.88 (1H, dd, V= 9.0 Hz, V- 2.2 Hz), 7.93 (1H, d, 4J~ 2.0 Hz), 8.04 (1H,
d, 3J= 9.0 Hz), 10.17 (1H, broad s, -NHCO-)

WO 2005/000794 PCT/F12004/000387
27
Example 20.
2-Hydroxy-3-[4-(2-hydroxyeftiyl)phenoxy]-2-meihyl-N-(3-metiiyl-4-
nitrophenyl)propionamide
2-Hydroxy-3-[4-(2-hydroxyethyl)phcaioxy]-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide was prepared as described in Example 1 starting from 4-
hydroxyphenyl alcohol (1.45 eq.), sodium hydride (2.9 eq.) and 2-methyloxirane-2-
carbocylic acid (3-methyl-4-nitrophenyl)amide (1 eq.). The crude product was
purified by flash chromatography using heptane/ethyl acetate as a gradient eluent (9:1
- 4:6). 'H NMR (400 MHz, DMSO-d6): 1.43 (3H, s), 2.53 (3H, s), 2.63 (2H, t, 3J=
7.1 Hz), 3.53 (2H, m), 3.94 (1H, d, V-( = 9.6 Hz), 4.17 (1H, d, 2J&m = 9.6 Hz), 4.56
(1H, t, 3J= 5.2 Hz, CH2OH), 6.17 (1H, broad s, -OH), 6.81 (2H, d, V= 8.7 Hz),
7.09 (2H, d), 7.88 (1H, dd, 3J= 9.0 Hz, 4J= 2.3 Hz), 7.93 (1H, d, V= 1.9 Hz), 8.04
(1H, d, 3J= 9.0 Hz), 10.13 (1H, broad s, -NHCO-).
Example 21.
3-(2,6-DicUorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(2,6-Dichlorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described Example 1 starting from 2,6-dichlorophenol
and l-(-epoxy-2-me;myl-N-(3-methyl-4-nitrophenyl)-2-propanamide.1H NMR (400
MHz, DMSO-de): 1.47 (3H, s), 2.53 (3H, s), 4.12 (1H, d, J = 9.0 Hz), 4.18 (1H, d, J
» 9.0 Hz), 6.14 (1H, s), 7.12-7.18 (1H, m), 7.43-7.46 (2 H, m), 7.86-7.90 (2H, m),
8.02-8.05 (1H, m), 10.11 (1H, s).
Example 22.
3-(4-Bromo-2-fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
3-(4-Bromo-2-fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide was prepared as described in Example 1 starting from 4-
bromo-2-fluorophenol and 1-(2-epoxy-2-methyl-N-(3-methyl-4-nitrophenyl)-2-
propanamide. 'H NMR (400 MHz, DMSO-dg): 1.43 (3H, s), 2.53 (3H, s), 4.08 (1H,
d, J = 9.9 Hz), 4.28 (1H, d, J = 9.9 Hz), 6.26 (1H, s), 7.15-7.22 (1H, m), 7.29-7.33 (1

WO 2005/000794 PCT/FI2004/000387
28
H, m), 7.46-7.50 (1H, m), 7.86 (1H, dd, J = 8.9 Hz, J = 2.3 Hz), 7.88 (1H, d, J = 1.9
Hz), 8.03 (1H, J = 8.9 Hz), 10.13 (1H, s).
Example 23.
3-(4-Oilorophaioxy)-2-hydroxy-2-methyl-N-(3-melliyl-4-nitrophenyl)-
propionamide
3-(4-CMorophenoxy)-2-hydroxy-2-meihyl-N-(3-methyl-4-nitroph«iyi)-
propionamide was prepared as described in Example 1 starting from/7-chlorophenol
and l,2-epoxy-2-methyl-N-[3-methyl-4-nitrophenyl]-2-propanamide. lHNMR (400
MHz, DMSO-de): 1.43 (3H, s), 2.53 (3H, s), 3.98 (1H, d, J= 9.7 Hz), 4.22 (1H, d, J
= 9.7 Hz), 6.23 (1H, s), 6.93-7.00 (2H, m), 7.28-7.32 (2H, m), 7.88 (1H, dd, J= 9.0
Hz, J= 2.2 Hz), 7.93 (1H, d, J= 1.9 Hz), 8.04 (1H, d, J= 9.0 Hz), 10.51 (1H, s).
Example 24.
3-(4-Bromophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(4-Bromophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example 1 starting fromp-bromophenol
and l-(-epoxy-2-methyl-N-[3-methyl-4-nitrophenyl]-2-prq)anamide. 1HNMR(400
MHz, DMSO-de): 1.43 (3H, s), 2.53 (3H, s), 3.97 (1H, d, J= 9.7 Hz), 4.21 (1H, d, J
= 9.7 Hz), 6.23 (1H, s), 6.88-6.93 (2H, m), 7.39-7.44 (2H, m), 7.88 (1H, dd, /= 9.0
Hz, J=22 Hz), 7.93 (1H, d, J= 1.8 Hz), 8.04 (1H, d, J= 9.0 Hz), 10.15 (1H, s).
Example 25.
2-Hydroxy-3-(4-methoxyphenoxy)-2-memyl-N-(3-methyl-4-nitrophenyl)-
propionamide
2-Hydroxy-3-(4-methoxyphenoxy)-2-memyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example 1 starting from/Mnethoxy-
phenol and l-(-epoxy-2-memyl-N-[3-memyl-4-nitrophenyl]-2-propanamide. lH
NMR (400 MHz, DMSO-dg): 1.42 (3H, s), 2.53 (3H, s), 3.68 (3H, s), 3.91 (1H, d, J=
9.5 Hz), 4.15 (1H, d, J= 9.5 Hz), 6.17 (1H, s), 6.80-6.87 (4H, m), 7.88 (1H, dd, J=
9.0 Hz, J= 2.2 Hz), 7.93 (1H, d, J= 2.0 Hz), 8.04 (1H, d, 7= 9.0 Hz), 10.13 (1H, s).

WO 2005/000794 PCT/FI2004/000387
29
Example 26.
3-(Benzo[ 1,3]dioxol-5-yloxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionaniide
3-(Benzo[ 1,3]dioxol-5-yioxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)-propionamide was prepared as described in Example 1 starting from 3,4-
methylenedioxyiphenol and l,2-epoxy-2-methyl-N-[3-methyl-4-nitrophenyl]-2-
propanamide. 'H NMR (400 MHz, DMSO-de): 1.41 (3H, s), 2.53 (3H, s), 3.90 (1H,
d, J= 9.6 Hz), 4.15 (1H, d, J= 9.6 Hz), 5.94 (2H, s), 6.18 (1H, s), 6.35 (1H, dd, J=
8.5 Hz, J= 2.5 Hz), 6.59 (1H, d, J= 2.5 Hz), 6.78 (1H, d, 7= 8.5 Hz), 7.88 (1H, dd,
J= 9.0 Hz, J = 2.2 Hz), 7.93 (1H, d, J= 1.6 Hz), 8.04 (1H, d, J= 9.0 Hz), 10.13 (1H,
Example 27.
3K3»-(Di-(e&oxyphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3K3,4-I)imethoxyphenoxy)-2-hydtoxy-2-methyl-N-(3-methyl-(riitropheriyl)-
propionamide was prepared as described in Example 1 starting from 3,4-dimethoxy-
phenol and l-(-(oxy-2-memyl-N-[3-methyl-4-nitrophenyl]-2-propanarnide. *H
NMR (400 MHz, DMSO-de): 1.43 (3H, s), 2.53 (3H, s), 3.67 (3H, s), 3.70 (3H, s),
3.91 (1H, d, J= 9.6 Hz), 4.17 (1H, d, /= 9.6 Hz), 6.17 (1H, s), 6.42 (1H, dd, /= 8.8
Hz, /= 2.8 Hz), 6.52 (1H, d, /= 2.8 Hz), 6.82 (1H, d, /= 8.8 Hz), 7.89 (1H, dd, 7=
9.0 Hz, J= 2.2 Hz), 7.94 (1H, d, /= 1.9 Hz), 8.04 (1H, d, J= 9.0 Hz), 10.13 (1H, s).
Example 28.
3K3»-(I-(fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(3,4-Difluorophenoxy)-2-hydroxy-2-methyl-N-(3-memyl-4-nitrophenyl)-
propionamide was prepared as described in Example 1 starting from 3,4-difluoro-
phenol and l-(-epoxy-2-memyl-N-[3-methyl-4-nitrophenyl]-2-propanamide. JH
NMR (400 MHz, DMSO-d*): 1.43 (3H, s), 2.53 (3H, s), 3.97 (1H, d, J= 9.8 Hz),
4.23 (1H, d, J= 9.8 Hz), 6.24 (1H, s), 6.72-6.79 (1H, m), 7.02-7.10 (1H, m), 7.20-
7.33 (1H, m), 7.88 (1H, dd, J= 9.0 Hz, /= 2.2 Hz), 7.93 (1H, d, J=* 1.9 Hz), 8.04
(1H, d, /= 9.9 Hz), 10.15 (1H, s).

WO 2005/000794 PCT/FI2004/000387
30
Example 29.
3-(2,4-DichIoro-3,5-dimethyIphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionainide
3-(2-(I-(cUoro-3,5--iimethylpheiioxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)-propionamide was prepared as described in Example 1 starting from
2,4-dichloro-3,5-dimethylphenol and l-(-epoxy-2-methyl-N-[3-methyi-4-nitro-
phenyl]-2-propanamide. *H NMR (400 MHz, DMSO-de): 1.46 (3H, s), 2.31 (3H, s),
2.36 (3H, s), 2.53 (3H, s), 4.41 (1H, d, J= 9.7 Hz), 4.21 (1H, d, J= 9.7 Hz), 6.25
(1H, s), 7.87 (1H, dd, /= 9.0 Hz, /= 2.3 Hz), 7.91 (1H, d, J= 1.9 Hz), 8.04 (1H, d, J
= 9.0 Hz), 10.12 (lH,s).
Example 30.
3-(6-BromonaphMen-2-yloxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)-propionamide
3-(6-Bromonaphtalen-2-yloxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example 1 starting from 6-
bromo-2-naphtol and l,2-epoxy-2-methyl-N-[3-methyl-4-nitropb.enyl]-2-propan-
amide. *H NMR (400 MHz, DMSO-de): 1.49 (3H, s), 2.53 (3H, s), 4.11 (1H, d, 7=
9.7 Hz), 4.35 (1H, d, J= 9.7 Hz), 6.29 (1H, s), 7.18 (1H, dd, /= 9.0 Hz, J= 2.5 Hz),
7.41 (1H, d, J= 2.4 Hz), 7.57 (1H, dd, J= 8.7 Hz, J= 2.0 Hz), 7.77 (1H, d, J= 9.1
Hz), 7.80 (1H, d, J= 9.3 Hz), 7.90 (1H, dd, J= 9.0 Hz, J= 2.2 Hz), 7.95 (1H, d, 1.9
Hz), 8.05 (1H, d, J= 9.0 Hz), 8.10 (1H, d, ./= 1.9 Hz), 10.21 (1H, s).
Example 31.
3-(4-Acetylamino-3-trifluoromethylphenoxy)-2-hydroxy-2-methyl-N-(3-
methyl-4-nitropb.enyl)propionamide
a) 4-Ainino-3-trifluoromethylphenol
4-Nitro-3-trifluoromethylphenol (0.414 g; 2.0 mmol) was dissolved in 25 ml
of glacial acetic acid and zinc dust (2,62 g; 40 mmol) was added in small portions
during 10 minutes allowing the temperature to rise up to +40°C. The mixture was
stirred for ten minutes and filtered. The dust was washed with 3 x 10 ml of glacial

WO 2005/000794 PCT/FI2004/000387
31
acetic acid and filtrate was evaporated to dryness to give 0.212 g of 4-amino-3-
trifluoromethylphenol. 'H NMR (400 MHz, DMSO-de): 4.86 (2H, s), 6.72 (1H, d, J
= 8.7 Hz), 6.74 (1H, d, J= 2.6 Hz), 6.78 (1H, dd, J= 8.7 Hz, J= 2.7 Hz), 8.91 (1H,
■)
b)N-(4-Hydroxy-2-trifluoromethylphenyl)acetamide
4-Amino-3-trifluoromethylphenol (0.212 g; 1.2 mmol) was dissolved in 10 ml
of glacial acetic acid under nitrogen athmosphere and acetic anhydride (0.3 ml; 3.0
mmol) was added followed with stirring for an hour at room temperature. Water (0.5
ml) was added into the reaction mixture and then evaporated to dryness. Toluene (50
ml) was added and the evaporation was repeated to give a quantitative yield of pure
N-(4-Hydroxy-2-trifluoromethylphenyl)acetamide. 'H NMR (400 MHz, DMSO-d6):
1.99 (3H, s), 7.01 (1H, dd, /= 8.6 Hz, J= 2.6 Hz), 7.02 (1H, d, J= 2.5 Hz), 7.19
(1H, d, J = 8.4 Hz), 9.33 (1H, s), 10.08 (1H, br s).
c) 3-(4-Ac»tylammo-3-trifluorome1hylphenoxy)-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl)propionamide
3-(4-Acetylammo-3-trifluoromethylphenoxy)-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl)propionamide was prepared as described in Example 1 starting
fromN-(4-hydroxy-2-trifluoromethylphenyl)acetamide and l,2-epoxy-2-methyl-N-
[3-methyl-4-nitrophenyl]-2-propanamide. !H NMR (400 MHz, DMSO-de): 1.46 (3H,
s), 2.00 (3H, s), 2.53 (3H, s), 4.07 (1H, d, /= 9.8 Hz), 4.32 (1H, d, 7= 9.8 Hz), 6.27
(1H, s), 7.19 (1H, d, J= 2.7 Hz), 7.22 (1H, dd, 7= 9.0 Hz, J= 2.5 Hz), 7.31 (1H, d, J
= 8.7 Hz), 7.88 (1H, dd, J= 9.0 Hz, J= 2.3 Hz), 7.93 (1H, d, /= 2.0 Hz), 8.04 (1H,
d,7= 9.0 Hz), 9.43 (1H, s), 10.17 (1H, s).
Example 32.
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(3,4,5-trifluorophenoxy)-
propionamide
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(3,4,5-trifluorophenoxy)-
propionamide was prepared as described in Example 1 starting from 3,4,5-trifluoro-
phenol and l-(-epoxy-2-methyl-N-[3-methyl-4-nitrophenyl]-2-propanamide. lK
NMR (400 MHz, DMSO-de): 1.42 (3H, s), 2.53 (3H, s), 3.98 (1H, d, J = 9.9 Hz),

WO 2005/000794 PCT/FI2004/000387
32
4.26 (1H, d, J= 9.0 Hz), 6.27 (1H, s), 6.92-7.02 (2H, m), 7.88 (1H, dd, J= 9.0 Hz, J
= 2.2 Hz), 7.92 (1H, d, J= 1.9 Hz), 8.04 (1H, d, J= 9.0 Hz), 10.14 (1H, s).
Example 33.
2-Hydroxy-3-(lH-indol-5-yloxy)-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
2-Hydroxy-3-(lH-indol-5-yloxy)-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example 1 starting from 4-hydroxyindole
and l,2-epoxy-2-methyl-N-[3-methyl-4-nitrophenyl]-2-propanamide. 1HNMR(400
MHz, DMSO-de): 1.49 (3H, s), 2.53 (3H, s), 4.10 (1H, d, /= 9.4 Hz), 4.23 (1H, d, J
= 9.4 Hz), 6.22 (1H, s), 6.31 (1H, d, /= 2.2 Hz), 6.47 (1H, dd, ./= 6.8 Hz, J= 1.5
Hz), 6.93-7.00 (2H, m), 7.12-7.17 (1H, m), 7.92 (1H, dd, J= 9.0 Hz, J= 2.1 Hz),
7.98 (1H, d, J= 1.6 Hz), 8.05 (1H, d, 7= 9.0 Hz), 10.24 (1H, s), 11.02 (1H, s).
Example 34.
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(4-methylsulfanyl-
phenoxy)propionamide
2-Hydroxy-2-methyl-N-(3-memyl-4-nitrophenyl)-3-(4-methylsulfenyl-
phenoxy)propionamide was prepared as described in Example 1 starting from 4-
(methylthio)phenol and l£-epoxy-2-merayl-N-[3-methyl-4-nitrophenyl]-2-
propanamide. JH NMR (400 MHz, DMSO-de): 1.43 (3H, s), 2.41 (3H, s), 2.53 (3H,
s), 3.96 (1H, d, J= 9.6 Hz), 4.20 (1H, d, J= 9.6 Hz), 6.21 (1H, s), 6.87-6.93 (2H, m),
7.17-7.25 (2H, m), 7.88 (1H, dd, J= 9.0 Hz, J= 2.3 Hz), 7.93 (1H, d, J= 2.0 Hz),
8.04 (1H, d, J= 9.0 Hz), 10.15 (1H, s).
Example 35.
3-(3-Huoro-4-nitro-phenoxy)-2-hydroxy-2-me1hyl-N-(3-memyl-4-nitro-
phenyl)propionamide
3-(3-Fluoro-4-nitro-phenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro--
phenyl)-propionamide was prepared as described in Example 1 starting from 3-
fluoro-4-nitrophenol and 2-methyl-oxirane-2-carboxylic acid (3-methyl-4-nitro-
phenyl)amide. 'H NMR (DMSO-de): 1.46 (3H, s), 2.53 (3H, s), 4.16 (1H, d, J=10.1
Hz), 4.41 (1H, d, J=10.1 Hz), 6.36 (1H, bs), 6.96 (1H, m), 7.22 (1H, m), 7.88 (1H,

WO 2005/000794 PCT/FI2004/000387
33
dd, J=9.0 Hz and 2.1 Hz), 7.90 (1H, d, J=2.1 Hz), 8.04 (1H, d, J=9.0 Hz), 8.24 (1H,
m), 10.19 (lH,s).
Example 36.
3-[4-(4-Chlorobenzoyl)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
3-[4-(4-C3ilorobenzoyl)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide was prepared as described in Example 1 starting from 4-
chloro-4'-hydroxybenzophenone and 2-methyloxirane-2-carbocylic acid (3-methyl-4-
nitrophenyl)amide. The crude product was purified by flash chromatography using
heptane/ethyl acetate as a gradient eluent. Crystallization from isopropanol.
'H NMR (400 MHz, DMSO-4,): 1.46 (3H, s), 2.53 (3H, s), 4.11 (1H, d, 2J%tm = 9.7
Hz), 4.33 (1H, d, 2Jgfm = 9.7 Hz), about 6.3 (1H, broad s, -OH), 7.09 (2H, d, 3J= 8.8
Hz), 7.62 (2H, d, 3J= 8.5 Hz), 7.70 (2H, d, V= 8.6 Hz), 7.72 (2H, d, 3J= 9.0 Hz),
7.89 (1H, dd, 3J= 9.0 Hz, V- 2.3 Hz), 7.94 (1H, d, V= 2.2 Hz), 8.05 (1H, d, 5J=
9.0 Hz), about 10.2 (1H, broad s, -NHCO-).
Example 37.
3-(3-CMorophenoxy)-2-hydroxy-2-memyl-N-(3-meiuiyl-(nitrophenyl)-
propionamide
3-(3-CUorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-mtrophenyi)-
propionamide was prepared as described in Example 1 starting from 3-chlorophenol
and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide. The crude
product was purified by flash chromatography using heptane/ethyl acetate as a
gradient eluent (10:90 - 40:90). Crystallization from toluene, m.p. 104-107 °C. *H
NMR (400 MHz, DMSO-d6): 1.43 (3H, s), 2.53 (3H, s), 4.00 (1H, d, V-( = 9.8 Hz),
4.26 (1H, d, 2/ge* = 9.8 Hz), 6.25 (1H, broad s, -OH), 6.88-6.91 (1H, m), 6.97-7.00
(1H, m), 7.02 (1H, t, V= 2.1 Hz), 7.28 (1H, t, 3J= 8.2 Hz), 7.89 (1H, dd, V- 9.0
Hz, 4J» 2.3 Hz), 7.94 (1H, d, 4J= 2.2 Hz), 8.04 (1H, d, 3J= 9.0 Hz), 10.17 (1H,
broad s, -NHCO-).
Example 38.
2-Hyd-(xy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-pentafluorophenyloxy-
propionamide

WO 2005/000794 PCT/FI2004/000387
34
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-pentafluorophenyloxy-
propionamide was prepared as described in Example 1 starting from pentafluoro-
phenol and l,2-epoxy-2-methyl-N-[3-methyl-4-nitrophenyl]-2-propanamide. *H
NMR (400 MHz, DMSO-de): 1.40 (3H, s), 2.53 (3H, s), 4.24 (1H, d, J= 10,2 Hz),
4.44 (1H, d, J= 10,2 Hz), 6.28 (1H, s), 7.87 (1H, dd, /= 9.0 Hz, J= 2.1 Hz), 7.89
(1H, d, J= 2.1 Hz), 8.05 (1H, d, 7= 8.9 Hz), 10.13 (1H, s).
Example 39.
(2iS)-3-(4-Huorophenoxy)-2-hydroxy-2-niethyl-N-(3-methyl-4-nitrophenyl)-
propionamide
(ZS)-3-(4-Fluorophenoxy)-2-hydroxy-2-niethyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example 3 starting fromp-fluorophenol
and (2R)-3-Bromo-2-hydroxy-2-methylpropanoic acid. *H NMR (400 MHz, DMSO-
de): 1.43 (3H, s), 2.53 (3H, s), 3.95 (1H, d, J- 9.6 Hz), 4.20 (1H, d, 7= 9.6 Hz), 6.21
(1H, s), 6.90-6.97 (2H, m), 7.06-7.12 (2H, m), 7.88 (1H, dd, J= 9.0 Hz, /= 2.3 Hz),
7.93 (1H, d, J= 1.9 Hz), 8.04 (1H, d, J= 9.0 Hz), 10.15 (1H, s).
Example 40.
N-(4-Cyano-3-memylphenyl)-3-(4-fluorophenoxy)-2-hydroxy-2-methyl-
propionamide
a) 4-Amino-2-methylbenzonitrile
3-Methyl-4-nitrobenzonitrile (1.0 g, 6 mmol) was dissolved in acetic acid (15
ml). Water (3.75 ml) was added and the mixture was heated between 90-95 °C. Iron
powder (2.5 g) was added during 1.5 hours and the resulting mixture was heated for 1
hour. Other portion of water (3.75 ml) was added and the heating was continued for
additional 2 hours. The solution was allowed to cool to room temperature and the
mixture was diluted with water (100 ml) and extracted with ethyl acetate (4 x 40 ml).
The organic phase was washed with 5 % NaHCCb (1 x 50 ml) and water (1 x 50 ml),
dried over Na2SC)-4 and evaporated. The crude product was used without further
purifications. *H NMR (DMSO-de): 2.28 (3H, s), 6.04 (2H, bs), 6.44 (1H, m), 6.48
(lH,m),7.31(lH,m).

WO 2005/000794 PCT/FI2004/000387
35
b)N-(4-Cyano-3-methylphenyl)-2-methylacrylainide
N-(4-Cyano-3-methylphenyl)-2-methylacrylamide was prepared as described
in Example 1 starting from 4-amino-2-methylbenzonitrile and methacryloyl chloride.
JH NMR (DMSO-do): 1.96 (3H, s), 2.45 (3H, s), 5.60 (1H, m), 5.85 (1H, m), 7.70
(2H, m), 7.81 (1H, m), 10.12 (1H, s).
c) 2-Methyloxirane-2-carboxylic acid (4-cyano-3-methylphenyl)amide
2-Methyloxirane-2-carboxylic acid (4-cyano-3-methylphenyl)amide was
prepared as described in Example 1 starting from N-(4-cyano-3-methylphenyl)-2-
methylacrylamide. ]H NMR (DMSO-d6): 1.54 (3H, s), 2.43 (3H, s), 2.99 (1H, d,
J=5.1 Hz), 3.04 (1H, d, J=5.1 Hz), 7.70 (2H, m), 7.89 (1H, m), 9.77 (1H, s).
d)N-(4-Cyano-3-methylphenyl)-3-(4-fluorophenoxy)-2-hydroxy-2-methyl-
propionamide
N-(4-Cyano-3-methylphenyl)-3-(4-£luorophenoxy)-2-hydroxy-2-methyl-
propionamide was prepared as described in Example 1 starting from 4-fluorophenol
and 2-methyl-oxirane-2-carboxylic acid (4-cyano-3-methylphenyl)amide. *H NMR
(DMSO-dg): 1.42 (3H, s), 2.44 (3H, s), 3.94 (1H, d, J=9.6 Hz), 4.18 (1H, d, J=9.6
Hz), 6.18 (1H, bs), 6.93 (2H, m), 7.08 (2H, m), 7.69 (1H, d, J=9.0 Hz), 7.78 (1H, dd,
J=9.0 Hz and 2.1 Hz), 7.93 (1H, d, J=2.1 Hz), 10.02 (1H, s).
Example 41.
3-(4-A(-(lanmio-3-fluorophenoxy)-N-(4-cyano-3-metiiylphenyl)-2-hydroxy-
2-methylpropionamide
3-(4-Acerylanunc-(3-fluorophenoxy)-N-(4-cyanc-3-memylphenyl)-2-hydTOxy-
2-methylpropionamide was prepared as described in Example 1 starting from N-(2-
fluoro-4-hydroxypb.enyl)acetamide and 2-methyl-oxirane-2-carboxylic acid (4-cyano-
3-methylphenyl)amide. JH NMR (DMSO-de): 1.41 (3H, s), 2.02 (3H, s), 2.44 (3H, s),
3.95 (1H, d, J=9.8 Hz), 4.26 (1H, d, J==9.8 Hz), 6.21 (1H, bs), 6.72 (1H, m), 6.86 (1H,
m), 7.56 (1H, m), 7.69 (1H, d, J=9.0 Hz), 7.78 (1H, dd, J=9.0 Hz and 2.2 Hz), 7.93
(1H, d, J=2.2 Hz), 9.51 (1H, s), 9.99 (1H, bs).

WO 2005/000794 PCT/FI2004/000387
36
Example 42.
3-(4-Cyano-3-fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide
3-(4-C-(ano-3-£liiorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example 1 starting from 2-fluoro-
4-hydroxybenzonitrile and 2-methyl-oxirane-2-carboxylic acid (3-methyl-4-
nitrophenyl)amide. *H NMR (DMSO-de): 1.46 (3H, s), 2.53 (3H, s), 4.11 (1H, d,
J=10.1 Hz), 4.371 (1H, d, J=10.1 Hz), 6.33 (1H, bs), 6.96 (1H, m), 7.18 (1H, m),
7.80 (1H, m), 7.88 (1H, dd, J=9.0 Hz and 2.1 Hz), 7.91 (1H, d, J=2.1 Hz), 8.03 (1H,
d, J=9.0 Hz), 10.21 (lH,s).
Example 43.
(2S)-3-(4-C-(no-3-fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide
(2S)-3-(4-C-(oO-fluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl--(nitro-
phenyl)propionamide was prepared as described in Example 3 starting from 2-fluoro-
4-hydroxybenzonitrile and (2R)-3-bromo-2-hydroxy-2-mefliyl-N-(3-methyl-4-nitro-
phenyl)propionamide according to the following procedure. A solution of 2-fluoro-4-
hydroxybenzonitrile (0.2 g, 1.4 mmol), (2R)-3-bromo-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl)propionamide (0.37 g, 1.2 mmol), K2CO3 (0.34 g, 2.5 mmol)
and benzyltriethylammonium chloride (0.028 g, 0.1 mmol) in methyl ethyl ketone (40
ml) was refluxed for 5 hours. The mixture was cooled to the room temperature and
evaporated. The residue was partitioned between ethyl acetate (50 ml) and water (50
ml) and the phases were separated. The organic phase was washed with 1 M Na2CO3
(4 x 20 ml) and water (1 x 20 ml), dried over Na2SC)-4 and evaporated. The crude
product was purified by flash chromatography (eluent CH2C12). *H NMR (DMSO-
de): 1.46 (3H, s), 2.53 (3H, s), 4.11 (1H, d, J=10.1 Hz), 4.371 (1H, d, J=10.1 Hz),
6.33 (1H, bs), 6.96 (1H, m), 7.18 (1H, m), 7.80 (1H, m), 7.88 (1H, dd, J=9.0 Hz and
2.1 Hz), 7.91 (1H, d, J=2.1 Hz), 8.03 (1H, d, J=9.0 Hz), 10.21 (1H, s).
Example 44.
3-(4-adoro-3-nitrophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide

WO 2005/000794 PCT/FI2004/000387
37
3-(4-(-(loro-3-nitrophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example 1 starting from 4-chloro-
3-nitrophenol and 2-methyloxirane-2-carboxylic acid (3-methyl-4-nitrophenyl)amide.
The crude product was purified by flash chromatography (dichloromethane - 0.2 %
methanol). !H NMR (400 MHz, DMSO-de): 1.45 (3H, s), 2.53 (3H, s), 4.10 (1H, d,
J=9.9 Hz), 4.36 (1H, d, J= 9.9 Hz), 6.28 (1H, s), 7.28 (1H, dd, J=9.0 Hz, J=3.0 Hz),
7.62 (1H, d, J=9.0 Hz), 7.68 (1H, d, J=3.0 Hz), 7.88 (1H, dd, J=9.0 Hz, J=2.3 Hz),
7.92 (1H, d, J=2.0 Hz), 8.03 (1H, d, J=9.0 Hz), 10.15 (1H, s).
Example 45.
3-(4-nuoro-3-trifluoromethylphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
3-(4-Fluoro-3-trifluoromethylphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide was prepared as described in Example 1 starting from 4-
fluoro-3-(trifluoromethyl)phenol and 2-methyloxirane-2-carboxylic acid (3-methyl-4-
nitrophenyl)amide. The crude product was purified by flash cnromatography
(dichloromethane - 1 % methanol). JH NMR (400 MHz, DMSO-do): 1.44 (3H, s),
2.53 (3H, s), 4.06 (1H, d, J=9.9 Hz), 4.32 (1H, d, J= 9.9 Hz), 6.23 (1H, s), 7.24-7.31
(2H, m), 7.38-7.43 (1H, m), 7.87 (1H, dd, J=9.0 Hz, J=2.1 Hz), 7.91 (1H, d, J=2.0
Hz), 8.03 (1H, d, J=9.0 Hz), 10.14 (1H, s).
Example 46.
2-Hydroxy-3-[4-(2-methoxyemyl)phenoxy]-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
2-Hydroxy-3-[4-(2-methoxyemyl)phenoxy]-2-memyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example 1 starting from 4-
methoxyethylphenol and 2-methyloxirane-2-carboxylic acid (3-methyl-4-nitro-
phenyl)amide. The crude product was purified by flash chromatography (dichloro-
methane -1 % methanol). JH NMR (400 MHz, DMSO-de): 1.43 (3H, s), 2.53 (3H,
s), 2.71 (2H, t, J=6.8 Hz), 3.21 (3H, s), 3.45 (2H, t, J-6.8 Hz), 3.94 (1H, d, J=9.5
Hz), 4.17 (1H, d, J= 9.5 Hz), 6.20 (1H, s), 6.82 (2H, d, J=7.8 Hz), 7.10 (2H, d, J=8.0
Hz), 7.89 (1H, d, J=9.0 Hz), 7.94 (1H, s), 8.03 (1H, d, J=8.8 Hz), 10.16 (1H, s).

WO 2005/000794 PCT/FI2004/000387
38
Example 47.
3-(4-Fluorophenoxy)-2-hydroxy-2-methyl-N-(2-methyl-3-nitrophenyl)-
propionamide
a)2-Methyl-N-(2-methyi-3-nitroph«iyl)acrylamide
2-Methyl-N-(2-methyl-3-nitrophenyl)aciylamide was prepared as described in
Example la starting from 2-methyl-3-nitroaniline and methacryloyl chloride. ]H
NMR (400 MHz, DMSO-de): 1.97 (3H, s), 2.23 (3H, s), 5.56 (1H, s), 5.90 (1H, s),
7.40-7.46 (1H, m), 7.57-7.60 (1H, m), 7.74-7.77 (1H, m), 9.71 (1H, s).
b) 2-Methyloxirane-2-carboxylic acid (2-methyl-3-nitrophenyl)amide
2-Methyloxirane-2-carboxylic acid (2-methyl-3-nitrophenyl)amide was
prepared as described in Example lb starting from 2-methyl-N-(2-methyl-3-
nitrophenyl)acrylamide. *H NMR (400 MHz, DMSO-de): 1.54 (3H, s), 2.19 (3H, s),
2.99 (1H, d, J=5.1 Hz), 3.09 (1H, d, J=5.1 Hz), 7.40-7.45 (1H, m), 7.57-7.60 (1H, m),
7.74-7.77 (1H, m), 9.47 (1H, s).
c)3-(4-Fluorophenoxy)-2-hydroxy-2-methyi-N-(2-memyl-3-
nitrophenyl)propionamide
3-(4-Fluorophenoxy)-2-hydroxy-2-methyl-N-(2-methyl-3-nitrophenyl)-
propionamide was prepared as described in Example lc starting from 4-fluorophenol
and 2-methyloxirane-2-carboxylic acid (2-methyl-3-nitrophenyl)amide. The crude
product was purified by flash chromatography (dichloromethane -1 % methanol). ]H
NMR (400 MHz, DMSO-ds): 1.44 (3H, s), 2.28 (3H, s), 3.96 (1H, d, J=9.5 Hz), 4.17
(1H, d, J= 9.5 Hz), 6.14 (1H, s), 6.93-6.97 (2H, m), 7.08-7.13 (2H, m), 7.41-7.45
(1H, m), 7.66-7.68 (1H, m), 7.72-7.75 (1H, m), 9.72 (1H, s).
Example 48.
3-(3-Cbloro-4-fluorophenoxy)-2-hydroxy-2-me1hyl-N-(2-methyl-3-
nitrophenyl)propionamide
3-(3-C3iloro-4-fluorophenoxy)-2-hydroxy-2-memyl-N-(2-methyl-3-mtro-
phenyl)propionamide was prepared as described in Example 1 starting from 3-chloro-

WO 2005/000794 PCT/FI2004/000387
39
4-fluorophenol and 2-methyloxirane-2-carboxylic acid (2-methyl-3-nitrophenyl)-
amide. The crude product was purified by flash chromatography (dichloromethane -
1 % methanol). 'H NMR (400 MHz, DMSO-de): 1.44 (3H, s), 2.27 (3H, s), 3.99 (1H,
d, J=9.8 Hz), 4.23 (1H, d, J= 9.8 Hz), 6.15 (1H, s), 6.92-6.97 (1H, m), 7.17-7.20 (1H,
m), 7.29-7.35 (1H, m), 7.41-7.46 (1H, m), 7.66-7.69 (1H, m), 7.72-7.75 (1H, m),
9.72 (1H, s).
Example 49.
2-Hydroxy-3-[4-(2-methoxyethyl)pheriOxy]-2-methyl-N-(2-meihyl-3-
nitrophenyl)propionainide
2-Hydroxy-3-[4-(2-methoxyethyl)phenoxy]-2-methyl-N-(2-methyl-3-riitro-
phenyl)propionamide was prepared as described in Example 1 starting from 4-
methoxyethylphenol and 2-methyloxirane-2-carboxylic acid (2-methyl-3-nitro-
phenyl)amide. The crude product was purified by flash chromatography
(dichloromethane - 2 % methanol). JH NMR (400 MHz, DMSO-de): 1.44 (3H, s),
2.28 (3H, s), 2.72 (2H, t, J=6.8 Hz), 3.22 (3H, s), 3.47 (2H, t, J=6.8 Hz), 3.94 (1H, d,
J=9.4 Hz), 4.15 (1H, d, J= 9.4 Hz), 6.11 (1H, s), 6.84 (2H, d, J=7.9 Hz), 7.12 (2H, d,
J=7.9 Hz), 7.41-7.45 (1H, m), 7.65-7.68 (1H, m), 7.72-7.75 (1H, m), 9.71 (1H, s).
Example 50.
{2-nuoro-([2-hydroxy-2-(3-methyl-4-nitrophenylcarbamoyl)propoxy]-
phenyl}carbamic acid ethyl ester
a) (2-Fluoro-4-hydroxyphenyl)carbamic acid ethyl ester
Ethyl chloroformate (0.37 ml, 3.9 mmol) was added to a stirring solution of 4-
amino-3-fluorophenol (0.5 g, 3.9 mmol) in 2 ml of 10 % NaOH. The reaction
mixture was heated at 80 °C for 30 min. After cooling, the solution was acidified
with hydrochloric acid to give the product rH NMR (400 MHz, DMSO-de): 1.20
(3H, t, J=7.0 Hz), 4.06 (2H, q, J=7.0 Hz), 6.53-6.59 (2H, m), 7.16-7.21 (1H, m), 8.79
(1H, s), 9.72 (1H, s).
b) {2-Fluoro-4-[2-hydroxy-2-(3-memyl-4-mtrophenylcarbamoyl)propoxy]-
phenyl}carbamic acid ethyl ester

WO 2005/000794 PCT/FI2004/000387
40
{2-Fluoro-4-[2-hydroxy-2-(3-methyl-4-nitrophenylcarbamoyl)propoxy]-
phenyl}carbamic acid ethyl ester was prepared as described in Example 1 starting
from (2-fluoro-4-hydroxyphenyl)carbaniic acid ethyl ester and 2-methyloxirane-2-
carboxylic acid (3-methyl-4-nitrophenyl)amide. The crude product was purified by
flash chromatography (dichloromethane -1.8 % methanol). lH NMR (400 MHz,
DMSO-dfi): 1.20 (3H, t, J=7.0 Hz), 1.43 (3H, s), 2.53 (3H, s), 3.97 (1H, d, J=9.7 Hz),
4.07 (2H, q, J=7.0 Hz), 4.22 (1H, d, J= 9.7 Hz), 6.21 (1H, s), 6.71-6.73 (1H, m),
6.83-6.87 (1H, m), 7.31-7.35 (1H, m), 7.86-8.05 (3H, m), 8.95 (1H, s), 10.12 (1H, s).
Example 51.
3-(4-Cyano-3-fluorophenoxy)-2-hydroxy-N-(3-hydroxymethyl-4-nitrophenyl)-
2-methylpropionamide
a) (5-Amino-2-nitrophenyl)methanol
To a solution of 5-amino-2-nitrobenzoic acid (3.0 g, 16.4 mmol) in 40 ml of
tetrahydrofuran was added 50 ml of borane-tetrahydrofuran complex (1.0 M solution
in THF). The mixture was heated under reflux for one hour. The usual workup
afforded the product. lK NMR (400 MHz, DMSO-de): 4.79 (2H, d, J=5.4 Hz), 5.37
(1H, t, J=5.4 Hz), 6.48 (1H, dd, J=9.0 Hz, J=2.5 Hz), 6.68 (2H, s), 6.99 (1H, d, J=2.5
Hz),7.94(lH,d,J=9.0Hz).
b)N-(3-Hyd-(oxymemyl-4-mtrophenyl)-2-methylacrylamide
N-(3-Hydroxymethyl-4-nitrophenyl)-2-methylacrylamide was prepared as
described in Example la starting from (5-Amino-2-nitrophenyl)methanol and
methaciyioyl chloride. *H NMR (400 MHz, DMSO-d*): 1.97 (3H, s), 4.85 (2H, d,
J=5.2 Hz), 5.56 (1H, t, J=5.2 Hz), 5.61 (1H, s), 5.90 (1H, s), 7.93 (1H, dd, J=9.0 Hz,
J=2.1 Hz), 8.11 (1H, d, J=9.0 Hz), 8.20 (1H, d, J=2.1 Hz), 10.32 (1H, s).
c) 2-Methyloxirane-2-carboxylic acid (3-hydroxymethyl-4-nitrophenyl)amide
2-Methyloxirane-2-carboxylic acid (3-hydroxymethyl-4-nitrophenyl)amide
was prepared as described in Example lb starting from N-(3-hydroxymethyl-4-
mtrophenyl)-2-methylacrylamide. !H NMR (400 MHz, DMSO-do): 1.55 (3H, s), 2.98
(1H, d, J=5.1 Hz), 3.07 (1H, d, J=5.1 Hz), 4.82 (2H, d, J=5.3 Hz), 5.53 (1H, t, J=5.3

WO 2005/000794 PCT/F12004/000387
41
Hz), 7.84 (1H, dd, J=8.9 Hz, J=2.4 Hz), 8.08 (1H, d, J=8.9 Hz), 8.24 (1H, d, J=2.4
Hz), 9.99 (1H, s).
d)3-(4-Cyano-3-fluorophenoxy)-2-hydroxy-N-(3-hydroxymethyl-4-
nitrophenyl)-2-methylpropionamide
3-(4-Cyano-3-fluorophenoxy)-2-hydroxy-N-(3-hydroxymethyl-4-nitrophenyl)-
2-methylpropionamide was prepared as described in Example lc starting from 2-
fluoro-4-hydroxybenzomtrile and 2-methyloxirane-2-carboxylic acid (3-hydroxy-
methyl-4-nitrophenyl)amide. The crude product was purified by flash chromato-
graphy (dichloromethane - 6.6 % methanol). ]H NMR. (400 MHz, DMSO-d6): 1.45
(3H, s), 4.13 (1H, d, J=10.0 Hz), 4.38 (1H, d, J= 10.0 Hz), 4.83 (2H, d, J=5.4 Hz),
5.51 (1H, t, J=5.4 Hz), 6.25 (1H, s), 6.94-6.98 (1H, m), 7.16-7.20 (1H, m), 7.77-7.82
(1H, m), 7.88 (1H, dd, J=9.0 Hz, J=2.4 Hz), 8.09 (1H, d, J=9.0 Hz), 8.34 (1H, d,
J=2.4 Hz), 10.24 (1H, s).
Example 52.
3-(4-Fluorophenylammo)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
A mixture of 2-methyloxirane-2-carboxylic acid (3-methyl-4-nitrophenyl)-
amide (0.2 g, 0.85 mmol), 4-fluoroaniline (0.18 g, 1.7 mmol) and sodium perchlorate
(0.21 g, 1.7 mmol) in 2 ml of acetonitrile was boiled under reflux for 6 hours. After a
workup of the reaction mixture, the crude product was purified by flash chromato-
graphy (dichloromethane -1% methanol). JH NMR (400 MHz, DMSO-de): 1.41
(3H, s), 2.51 (3H, s), 3.10 (1H, dd, J=12.7 Hz, J=4.6 Hz), 3.41 (1H, dd, J= 12.7 Hz,
J=7.7 Hz), 5.26 (1H, m), 6.02 (1H, s), 6.62-6.66 (2H, m), 6.84-6.89 (2H, m), 7.79-
7.83 (2H, m), 8.02 (1H, d, J=8.9 Hz), 9.99 (1H, s).
Example 53.
2-Hydroxy-2-me1hyi-N-(3-memyl-(mtrophenyl)-3-(4-trifluoix)me&ylphenyl-
amino)propionamide
2-Hydroxy-2-memyl-N-(3-memyl-4-mtrophenyl)-3-(4-trifluoromethylphenyl-
amino)propionamide was prepared as described in Example 52 starting from 4-
(trifluoromethyl)aniline an4 2-methyloxirane-2-carboxylic acid (3-methyl-4-nitro-

WO 2005/000794 PCT/FI2004/000387
42
phenyl)amide. The crude product was purified by flash chromatography (dichloro-
methane - 1.5 % methanol). *H NMR (400 MHz, DMSO-dg): 1.42 (3H, s), 2.51 (3H,
s), 3.23 (1H, dd, J=13.3 Hz, J=5.0 Hz), 3.51 (1H, dd, J= 13.3 Hz, J=7.0 Hz), 6.06
(1H, s), 6.18 (1H, m), 6.77 (2H, d, J=8.4 Hz)), 7.31 (2H, d, J=8.4 Hz), 7.79-7.83
(2H, m), 8.01 (1H, d, J=8.9 Hz), 10.02 (1H, s).
Example 54.
2-Hydroxy-3-(4-methoxy-3-trifluoromethylphenylarnino)-2-methyl-N-(3-
methyl-4-nitrophenyl)propionainide
2-Hydroxy-3-(4-methoxy-3-trifluoromethylphenylamino)-2-me(hyl-N-(3-
methyl-4-nitrophenyl)propionamide was prepared as described in Example 52
starting from 3-amino-6-methoxybenzotrifluoride and 2-methyloxirane-2-carboxylic
acid (3-methyl-4-nitrophenyl)amide. The crude product was purified by flash
chromatography (dichloromethane - 1.5 % methanol). lH NMR (400 MHz, DMSO-
de): 1.41 (3H, s), 2.51 (3H, s), 3.12 (1H, dd, J=13.0 Hz, J=*4.8 Hz), 3.45 (1H, dd,
JN13.0 Hz, J=7.7 Hz), 3.71 (3H, s), 5.42 (1H, m), 6.00 (1H, s), 6.88 (1H, dd, J«=8.9
Hz, J=2.7 Hz), 6.92 (1H, d, J=2.7 Hz), 6.97 (1H, d, J=8.9 Hz), 7.78 (1H, dd, J=8.9
Hz, J=2.3 Hz), 7.81 (1H, d, J=1.9 Hz), 8.00 (1H, d, J=8.9 Hz), 9.98 (1H, s).
Example 55.
3-(4-Cyanophenylamino)-2-hydroxy-2-memyl-N-(3-memyl-(riitrophenyl)-
propionamide
3-4-Cyanophenylainino)-2-hydroxy-2-memyl-N-(3-memyl-(riitrophenyl)-
propionamide was prepared as described in Example 52 starting from 4-aminobenzo-
nitrile and 2-methyloxirane-2-carboxylic acid (3-methyl-4-nitrophenyl)amide. The
crude product was purified by flash chromatography (dichloromethane - 5 %
methanol). 'H NMR (400 MHz, DMSO-de): 1.41 (3H, s), 2.52 (3H, s), 3.25 (1H, dd,
J=13.5 Hz, J=5.3 Hz), 3.52 (1H, dd, J= 13.5 Hz, J=7.0 Hz), 6.08 (1H, s), 6.53 (1H,
m), 6.75 (2H, d, J=8.8 Hz)), 7.39 (2H, d, J=8.8 Hz), 7.79-7.83 (2H, m), 8.01 (1H, d,
J=8.9 Hz), 10.02 (1H, s).
Example 56.
3-(3-CWoro-4-(yanophenylammo)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide

WO 2005/000794 PCT/FI2004/000387
43
3-(3-Chloro-4-(yanophenylamino)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example 52 starting from 4-
ammo-2-chlorobenzonitrile and 2-methyloxirane-2-carboxylic acid (3-methyl-4-
nitrophenyl)amide. The crude product was purified by flash chromatography
(dichloromethane - 3 % methanol). ]H NMR (400 MHz, DMSO-d*): 1.40 (3H, s),
2.52 (3H, s), 3.27 (1H, dd, J=13.8 Hz, J=5.5 Hz), 3.55 (1H, dd, J=13.8 Hz, J=6.9
Hz), 6.12 (1H, s), 6.72 (1H, dd, J=8.8 Hz, J=2.2 Hz), 6.90 (1H, d, J=2.2 Hz), 6.95-
6.98 (1H, m), 7.46 (1H, d, J=8.7 Hz), 7.80 (1H, dd, J=8.9 Hz, J=2.3 Hz), 7.83 (1H,
d, J=2.0 Hz), 8.02 (1H, d, J=8.9 Hz), 10.05 (1H, s).
Example 57.
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(pyridin-3-yloxo)propion-
amide
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(pyridin-3-yloxo)propion-
amide was prepared as described in Example 1 starting from 3-hydroxypyridine and
2-methyloxirane-2-carboxylic acid (3-metb.yl-4-nitrophenyl)amide. The crude
product was purified by flash chromatography (dichloromethane - 9 % methanol). *H
NMR (400 MHz, DMSO-de): 1.45 (3H, s), 2.53 (3H, s), 4.06 (1H, d, J=9.8 Hz), 4.31
(1H, d, J= 9.8 Hz), 6.26 (1H, s), 7.28-7.32 (1H, m), 7.38-7.41 (1H, m), 7.87-7.93
(2H, m), 8.03 (1H, d, J=8.9 Hz), 8.15-8.17 (1H, m), 8.26 (1H, d, J=2.4 Hz), 10.15
(lH,s).
Example 58.
2-Hydroxy-2-memyl-N-(3-memyl-4-mtrophenyl)-3-(pyridin-4-yloxo)propion-
amide
2-Hydroxy-2-methyl-N-(3-memyl-4-mtrophenyl)-3-(pyridin-4-yloxo)propion-
amide was prepared as described in Example 1 starting from 4-hydroxypyridine and
2-methyloxirane-2-carboxylic acid (3-methyl-4-nitrophenyl)amide. The crude
product was purified by flash chromatography (dichloromethane - 7 % methanol).
!H NMR (400 MHz, CDQ3): 1.62 (3H, s), 2.63 (3H, s), 4.08 (1H, d, J=9.2 Hz), 4.46
(1H, d, J= 9.2 Hz), 6.79 (2H, d, J=5.1 Hz), 7.57 (1H, d, J=9.0 Hz), 7.66 (1H, s), 8.05
(1H, d, J=8.8 Hz), 8.35 (2H, d, J=5.1 Hz), 9.14 (1H, s).

WO 2005/000794 PCT/FI2OO4/000387
44
Example 59.
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(pyridin-2-yloxo)propion-
amide
2-Hydroxy-2-methyl-N-(3-methyl-(nitrophenyl)-3-(yridin-2-yloxo)propion-
amide was prepared as described in Example 1 starting from 2-hydroxypyridine and
2-methyloxirane-2-carboxylic acid (3-methyl-4-nitrophenyl)amide. The crude
product was purified by flash chromatography (dichloromethane - 2 % methanol).
'H NMR (400 MHz, CDC13): 1.53 (3H, s), 2.61 (3H, s), 4.58 (1H, d, J=12.3 Hz),
4.72 (1H, d, J= 12.3 Hz), 6.87 (1H, d, J=8.3 Hz), 7.00 (1H, t, J=6.1 Hz), 7.56 (1H, d,
J=8.9 Hz), 7.64-7.69 (2H, m), 7.81 (1H, s), 8.03 (1H, d, J=8.9 Hz), 8.11 (1H, d, J=5.0
Hz), 9.33 (1H, s).
Example 60.
3-(2-Chloropyridin-3-yloxo)-2-hydroxy-2-methyl-N-(3-memyl-4-nitro-
phenyl)propionamide
3-(2-CMoropyridin-3-yloxo)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example 1 starting from 2-chloro-
3-hydroxypyridine and 2-methyloxirane-2-carboxylic acid (3-methyl-4-nitrophenyl)- .
amide. The crude product was purified by flash chromatography (dichloromethane -
2 % methanol). *H NMR (400 MHz, DMSO-de): 1.47 (3H, s), 2.53 (3H, s), 4.18 (1H,
d, J=9.9 Hz), 4.31 (1H, d, J= 9.9 Hz), 6.28 (1H, s), 7.35-7.39 (1H, m), 7.63 (1H, d,
J=8.2 Hz), 7.77-7.97 (3H, m), 8.04 (1H, d, J=8.9 Hz), 10.13 (1H, s).
Example 61.
N-(4-Fluoro-3-metiiylphenyl)-3-(4-fluorophenoxy)-2-hydroxy-2-methyl-
propionamide
a) N-(4-Fluoro-3-methylphenyl)-2-methylacrylamide
N-(4-Fluoro-3-methylphenyl)-2-methylacrylamide was prepared as described
in Example la starting from 4-fluoro-3-methylaniline and methacryloyl chloride. *H
NMR (400 MHz, DMSO-de): 1.94 (3H, s), 2.21 (3H, s), 5.50 (1H, s), 5.78 (1H, s),
7.05-7.10 (1H, m), 7.48-7.51 (1H, m), 7.57-7.59 (1H, m), 9.75 (1H, s).

WO 2005/000794 PCT/FI2004/000387
45
b) 2-Methyloxirane-2-carboxylic acid (4-fluoro-3-methylphenyl)amide
2-Methyloxirane-2-carboxylic acid (4-fluoro-3-methylphenyl)amide was
prepared as described in Example lb starting from N-(4-fluoro-3-methylphenyl)-2-
methylacrylainide. JH NMR (400 MHz, DMSO-dg): 1.52 (3H, s), 2.19 (3H, s), 2.94
(1H, d, J=5.3 Hz), 2.99 (1H, d, J=5.3 Hz), 7.02-7.07 (1H, m), 7.44-7.48 (1H, m),
7.56-7.59 (1H, m), 9.40 (1H, s).
c)N-(4-Fluoro-3-methylphenyl)-3-(4-fluorophenoxy)-2-hydroxy-2-
methylpropionamide
N-(4-Fluoro-3-methylphenyl)-3-(4-fluorophenoxy)-2-hydroxy-2-methyl-
propionamide was prepared as described in Example lc starting from 4-fluorophenol
and 2-methyloxirane-2-carboxylic acid (4-fluoro-3-methylphenyl)amide. The crude
product was purified by flash chromatography (dichloromethane - 1.4 % methanol).
!H NMR (400 MHz, DMSO-de): 1.40 (3H, s), 2.20 (3H, s), 3.92 (1H, d, J=9.5 Hz),
4.17 (1H, d, J= 9.5 Hz), 6.03 (1H, s), 6.91-6.95 (2H, m), 7.03-7.10 (3H, m), 7.53-
7.57 (1H, m), 7.66-7.68 (1H, m), 9.62 (1H, s).
Example 62.
3-(4-Acetylarnmophenoxy)-N-(4-fluoro-3-mefliylphenyl)-2-hydroxy-2-
methylpropionamide
3K4-Acetylaminophenoxy)-N-(4-fluoro-3-methylphenyl)-2-b.ydroxy-2-
methylpropionamide was prepared as described in Example 61 c starting from 4-
acetamidophenol and 2-methyloxirane-2-carboxyiic acid (4-fluoro-3-methylphenyl)--
amide. !H NMR (400 MHz, DMSO-d*): 1.40 (3H, s), 2.00 (3H, s), 2.20 (3H, s), 3.90
(1H, d, J=9.5 Hz), 4.15 (1H, d, J= 9.5 Hz), 6.03 (1H, s), 6.84 (2H, d, J=8.7 Hz), 7.03-
7.08 (1H, m), 7.44 (2H, d, J=8.7 Hz), 7.54-7.57 (1H, m), 7.67-7.69 (1H, m), 9.62
(1H,S),9.75(1H,S).
Example 63.
3-(3-(-(oro-4-cyanophenoxy)-2-hydroxy-2-metiiyl-N-(3-methyi-4-nitro-
phenyl)propionamide

WO 2005/000794 PCT/FI2004/000387
46
3-(3-Chloro-4-(yanophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example 1 starting from 2-chloro-
4-hydroxybenzonitrile and 2-methyloxirane-2-carboxylic acid (2-methyl-3-nitro-
phenyl)amide. The crude product was purified by flash chromatography (dichloro-
methane - 1.2 % methanol). 'H NMR (400 MHz, DMSO-de): 1.44 (3H, s), 2.53 (3H,
s), 4.13 (1H, d, J=10.1 Hz), 4.39 (1H, d, J= 10.1 Hz), 6.29 (1H, s), 7.09 (1H, dd,
J=8.8 Hz, J=2.4 Hz), 7.36 (1H, d, J=2.4 Hz), 7.84-7.91 (3H, m), 8.03 (1H, d, J=8.9
Hz), 10.15 (1H, s).
Example 64.
3-(4-Cyano-3-fluorophenoxy)-2-hydroxy-2-methyl-N-(2-methyl-4-nitro-
phenyl)propionamide
a)2-Methyl-N-(2-methyl-4-nitropb.enyl)acrylamide
2-Methyl-N-(2-methyl-4-nitrophenyl)acrylamide was prepared as described in
Example la starting from 2-methyl-4-nitroaniline and methacryloyl chloride. *H
NMR (400 MHz, DMSO-de): 1.98 (3H, s), 2.34 (3H, s), 5.59 (1H, s), 5.91 (1H, s),
7.74 (1H, d, J=8.8 Hz), 8.07 (1H, dd, J=8.8 Hz, J=2.7 Hz), 8.15 (1H, d, J=2.6 Hz),
9.53 (1H, s).
b) 2-Methyloxirane-2-carboxylic acid (2-methyl-4-nitrophenyl)amide
2-Methyloxirane-2-carboxylic acid (2-methyl-4-nitrophenyl)amide was
prepared as described in Example lb starting from 2-methyl-N-(2-methyl-4-nitro-
phenyl)acrylamide. *H NMR (400 MHz, DMSO-d6): 1.55 (3H, s), 2.30 (3H, s), 3.03
(1H, d, J=5.1 Hz), 3.15 (1H, d, J=5.1 Hz), 7.86 (1H, d, J==8.9 Hz), 8.08 (1H, dd,
J=8.9 Hz, J=2.6 Hz), 8.15 (1H, d, J=2.5 Hz), 9.13 (1H, s).
c)3-(4-}yano-3-fluoiophenoxy)-2-hydroxy-2-memyl-N-2-methyl-4-
nitrophenyl)propionamide
3-(4-Cyano-3-fluorophenoxy)-2-hydroxy-2-memyl-N-(2-methyl-(nitro-
phenyl)propionamide was prepared as described in Example lc starting from 2-
fluoro-4-hydroxybenzonitrile and 2-methyloxirane-2-carboxylic acid (2-methyl-4-
nitrophenyl)amide. The crude product was purified by flash chromatography

WO 2005/000794 PCT/FI2004/000387
47
(dichloromethane - 1.3 % methanol). lH NMR (400 MHz, DMSO-d*): 1.46 (3H, s),
2.37 (3H, s), 4.13 (1H, d, J=10.1 Hz), 4.37 (1H, d, J= 10.1 Hz), 6.51 (1H, s), 6.95-
6.98 (1H, m), 7.17-7.21 (1H, m), 7.78-7.83 (1H, m), 8.05-8.12 (2H, m), 8.18 (1H, d,
J=2.3 Hz), 9.57 (1H, s).
Example 65.
3-(3-chloro-4-cyanophenoxy)-2-hydroxy-2-methyl-N-(2-methyl-4-iiitro-
phenyl)propionamide
3-(3-Chloro-4-cyanophenoxy)-2-hydroxy-2-methyl-N-(2-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example 64c starting from 2-
chloro-4-hydroxybenzonitrile and 2-methyloxirane-2-carboxylic acid (2-methyl-4-
nitrophenyl)amide. The crude product was purified by flash chromatography
(dichloromethane -1.3 % methanol). *H NMR (400 MHz, DMSO-d-(): 1.46 (3H, s),
2.37 (3H, s), 4.15 (1H, d, J=10.1 Hz), 4.39 (1H, d, J= 10.1 Hz), 6.51 (1H, s), 7.10
(1H, dd, J=8.8 Hz, J=2.4 Hz), 7.37 (1H, d, J=2.4 Hz), 7.86 (1H, d, J=8.8 Hz), 8.05-
8.12 (2H, m), 8.18 (1H, d, J=2.3 Hz), 9.56 (1H, s).
Example 66.
3-(4-Cyano-3-fluorophenoxy)-N-(3-foimyl-4-nitrophenyl)-2-hydroxy-2-
methylpropionamide
3-(4-Cyano-3-fluorophenoxy)-2-hydroxy-N-(3-hydroxymethyl-4-nitrophenyl)-
2-methylpropionamide (0.2 g, 0.51 mmol) was dissolved in dichloromethane (10 ml)
and manganese(rV) oxide (0.4 g, 4.6 mmol) was added. The mixture was stirred at
room temperature for 48 hours. The solid oxidant was removed by filtration and the
solvent was evaporated. The crude product was purified by flash chromatography
(dichloromethane - 3 % memanol). *H NMR (400 MHz, DMSO-de): 1.45 (3H, s),
4.13 (1H, d, J=10.0 Hz), 4.38 (1H, d, J= 10.0 Hz), 6.32 (1H, s), 6.94-6.97 (1H, m),
7.16-7.20 (1H, m), 7.77-7.82 (1H, m), 8.18-8.24 (2H, m), 8.36 (1H, d, J=2.1 Hz),
10.28 (1H, s), 10.55 (1H, s).
Example 67.
3-[4-(2-Dmiemylammoemoxy)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide

WO 2005/000794 PCT/FI2004/000387
48
a) [2-(4-Benzyloxyphenoxy)ethyl]dimethylamine
4-(Benzyloxy)phenol (2.89 g, 0.01443 mol) in dimethylfonnamide (15 ml)
and 2-(dimethylamino)ethyl chloride hydrochloride (2.32 g, 0.01611 mol) were
added simultaneously in small portions to a 55-65% sodium hydride dispersion in
mineral oil (0.033 mol) in dimethylfonnamide (5 ml) at 0 °C. Then the mixture was
allowed to warm to 90 °C, and stirring was continued for 1.5 h. The cooled mixture
was poured into water. The resultant mixture was extracted with toluene. The
combined extracts were washed with 2.5 M NaOH and water and dried over Na2SC)-4.
Toluene was evaporated and the residual product was used as such in the next step.
!H NMR (300 MHz, DMSCW*): 2.20 (6H, s), 2.58 (2H, t, 3J= 5.9 Hz), 3.96 (2H, t,
3J= 5.9 Hz), 5.03 (2H, s), 6.85 (2H, d, 3J= 9.3 Hz), 6.92 (2H, d, 3J= 9.3 Hz), 7.30-
7.44 (5H, m).
b) 4-(2-Dimethylaminoethoxy)phenol
A stirred solution of [2-(4-benzyloxyphenoxy)ethyl]dimethylamine (3.36 g,
0.01238 mol) in the mixture of 6 M HC1 (67 ml) and ethanol (33.5 ml) was refluxed
for 6.5 h. Then ethanol was evaporated and pH was adjusted to 8 with 2.5 M NaOH.
The product was extracted into ethyl acetate. The extracts were washed with water
and dried over Na2SO4. Removal of solvent under reduced pressure gave a raw
product which was purified by flash chromatography on silica gel using heptane/ethyl
acetate (9:1- 6:4) as a gradient eluent *H NMR (300 MHz, DMSO-*fc): 2.20 (6H, s),
2.57 (2H, t, 3J= 5.9 Hz), 3.92 (2H, t, 3J= 5.9 Hz), 6.65 (2H, d, V= 9.1 Hz), 6.74
(2H, d, 3J= 9.0 Hz), 8.85 (1H, s, -OH).
c)3-[4-(2-Dimemylammoemoxy)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-
4-nitrophenyl)propionamide
3-[4-(2-Dimemylammoethoxy)phenoxy]-2-hydroxy-2-methyl-N-(3-memyl-4-
nitrophenyl)propionamide was prepared as described in Example lc starting from 4-
(2-dimethylaminoethoxy)phenol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-
nitrophenyl)amide. The product was extracted at pH 8. The crude product was
purified by flash chromatography using dichloromethane/methanol as a gradient
eluent (methanol 0-20 %). Crystallization from toluene. *H NMR (400 MHz, DMSO-
d6): 1.42 (3H, s), 2.19 (6H, s), 2.53 (3H, s), 2.57 (2H, t, 3J= 5.8 Hz), 3.90 (1H, d,

WO 2005/000794 PCT/FI2004/000387
49
2Jgem = 9.6 Hz), 3.95 (2H, t, 3J= 5.9 Hz), 4.14 (1H, d, 2Jgem = 9.5 Hz), 6.18 (1H, s, -
OH), 6.83 (4H, s), 7.88 (1H, dd, 3J= 9.0 Hz, 4J= 2.3 Hz), 7.93 (1H, d, 4J= 1.8 Hz),
8.04 (1H, d, 3J= 9.0 Hz), 10.14 (1H, s, -NHCO-).
Example 68.
3-(4-Cyanomethylphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(4-Cy-(nomethylphenoxy)-2-hydroxy-2-methyl-N-(3-meftyl-(mtrophenyl)-
propionamide was prepared as described in Example lc starting from 4-hydroxy-
benzyl cyanide and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)-
amide. The crude product was purified by flash cbromatography using heptane/ethyl
acetate as a gradient eluent (9:1-7:3). Crystallization from toluene, m.p. 143-145 °C.
!H NMR (300 MHz, DMSO-d6): 1.43 (3H, s), 2.53 (3H, s), 3.92 (2H, s), 3.98 (1H, d,
2Jgem = 9.7 Hz), 4.21 (1H, d, -( = 9.7 Hz), 6.17 (1H, broad s, -OH), 6.94 (2H, d, 3J
= 8.7 Hz), 7.23 (2H, d, 3J= 8.7 Hz), 7.87 (1H, dd, 3J= 9.0 Hz, V- 2.2 Hz), 7.92
(1H, s), 8.03 (1H, d, 3J= 8.9 Hz), 10.09 (1H, broad s, -NHCO-).
Example 69.
3-[4-(2-CMoroethyl)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide
3-[4-(2-(-(oroethyl)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-rjitro-
phenyl)propionamide was prepared as described in Example lc starting from 4-(2-
chloroetiiyl)phenol (A. C. Spivey et al. J. Org. Chem. 65 (2000) 5253; P. G. Baraldi
et al. J. Med. Chem. 45 (2002) 115) and 2-methyl-oxirane-2-carbocylic acid (3-
methyl-4-nitrophenyl)amide. The crude product was purified twice by flash
chromatography using first heptane/ethyl acetate as a gradient eluent (9:1-8:2) and
then only dichloromethane. lE NMR (400 MHz, DMSO-rf*): 1.43 (3H, s), 2.53 (3H,
s), 2.93 (2H, t, 3J= 7.1 Hz), 3.77 (2H, t, V= 7.1 Hz), 3.95 (1H, d, 2Jgm = 9.6 Hz),
4.19 (1H, d, 2Jgem = 9.6 Hz), about 6.2 (1H, broad s, -OH), 6.85 (2H, d, 3J= 8.6 Hz),
7.16 (2H, d, 3J= 8.7 Hz), 7.89 (1H, dd, 3J= 9.0 Hz, 4J= 2.3 Hz), 7.94 (1H, d, 4J=
2.2Bz), 8.04(1H, d,3J= 9.0Hz), about 10.2 (1H,broads, -NHCO-).

WO 2005/000794 PCT/FI2004/000387
50
Example 70.
2-Hydroxy-3-(4-hydroxymethylphenoxy)-2-methyl-N-(3-methyl--(nitro-
phenyl)propionamide
2-Hydroxy-3-(4-hydroxymethylpheiioxy)-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example lc starting from 4-
hydroxybenzyl alcohol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitro-
phenyl)amide. The crude product was purified by flash chromatography using
heptane/ethyl acetate as a gradient eluent (95:5-25:75). 'H NMR (400 MHz, DMSO-
d6): 1.43 (3H, s), 2.53 (3H, s), 3.95 (1H, d, 2Jtpn = 9.6 Hz), 4.18 (1H, d, 2Jtem = 9.6
Hz), 4.39 (2H, d, 3J= 5.3 Hz), 5.05 (1H, t, 3J= 5.7 Hz), 6.22 (1H, s, -OH), 6.86 (2H,
d, 3J= 8.6 Hz), 7.19 (2H, d, 3J= 8.8 Hz), 7.89 (1H, dd, 3J= 9.0 Hz, V= 2.3 Hz),
7.94 (1H, d, 4J= 2.2 Hz), 8.04 (1H, d, 3J= 9.0 Hz), 10.16 (1H, s, -NHCO-).
Example 71.
2-Hydroxy-3-(4-hydroxyphenoxy)-2-methyl-N-(3-mefliyl-4-nitrophenyl)-
propionamide
2-Hydroxy-3-(4-hydroxyphenoxy)-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example lc starting from hydroquinone
and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide. The crude
product was purified by flash chromatography using heptane/ethyl acetate as a
gradient eluent (9:1-6:4). !H NMR (400 MHz, DMSO-d*): 1.40 (3H, s), 2.53 (3H, s),
3.86 (1H, d, 27g«, = 9.4 Hz), 4.10 (1H, d, %. = 9.4 Hz), 5.76 (1H, broad s, -OH),
6.63 (2H, d, 3J= 9.0 Hz), 6.73 (2H, d, 3J= 9.0 Hz), 7.88 (1H, dd, 3J= 9.0 Hz, 4J=
2.4 Hz), 7.93 (1H, d, V- 2.1 Hz), 8.04 (1H, d, 3J= 9.0 Hz), 8.92 (1H, broad s,
ArOH), 10.13 (1H, broad s, -NHCO-).
Example 72.
3-(3-Cyanophenoxy)-2-hyd-(xy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(3-Cyanophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example lc starting from 3-cyanophenol
and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide. The crude
product was purified by flash chromatography using heptane/ethyl acetate as a

WO 2005/000794 PCT/FI2004/000387
51
gradient eluent Crystallization from toluene, m.p. 107-110 °C. lH NMR (300 MHz,
DMSO-40: 1.44 (3H, s), 2.53 (3H, s), 4.06 (1H, d, V-( = 10.0 Hz), 4.31 (1H, d,
2Jgem = 9.9 Hz), about 6.3 (1H, broad s, -OH), 7.27 (1H, m), 7.38 (1H, dt, V= 7.5 Hz,
V= 1.3 Hz), 7.43 (1H, m), 7.46 (1H, t, V= 7.8 Hz), 7.87 (1H, dd, 3J= 9.0 Hz, 4J=
2.3 Hz), 7.91 (1H, d, V= 9.0 Hz, 4J= 1.9 Hz), 8.03 (1H, d, 3J= 9.0 Hz), about 10.1
(1H, broad s, -NHCO-).
Example 73.
3-(3-Fluoro-5-trifluorometbylphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
3-(3-Fluoro-5-trifluoromethylphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide was prepared as described in Example lc starting from 3-
fluoro-5-(trifluoromethyl)phenol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-
nitrophenyl)amide. The crude product was purified by flash chromatography using
heptane/ethyl acetate as a gradient eluent. Crystallization from toluene/heptane. !H
NMR '100 MHz, DMSCwfc): 1.44 (3H, s), 2.53 (3H, s), 4.15 (1H, d, 2Jgem » 10.0
Hz), 4.37 (1H, d, 2Jzm = 10.0 Hz), 6.26 (1H, broad s, -OH), 7.12 (1H, s), 7.19 - 7.22
(2H, m), 7.87 (1H, dd, 3J= 8.9 Hz, V= 2.3 Hz), 7.92 (1H, d, 4J= 1.9 Hz), 8.03 (1H,
d, 3J= 9.0 Hz), 10.15 (1H, broad s, -NHCO-).
Example 74.
3-(3,5-Difluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(3,5-Difluorophenoxy)-2-hydroxy-2-me&yl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example lc starting from 3,5-difluoro-
phenol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide. The
crude product was purified by flash chromatography using heptane/ethyl acetate as a
gradient eluent (95:5 - 70:30). Crystallization from toluene, m.p. 104-106 °C. *H
NMR (400 MHz, DMSO-d*): 1.43 (3H, s), 2.53 (3H, s), 4.01 (1H, d, 2Jgan = 9.9 Hz),
4.27 (1H, d, 2Jgem - 9.8 Hz), about 6.3 (1H, broad s, -OH), 6.71 (2H, dd, 3JHF = 9.5
Hz, 4Jm = 2.1 Hz), 6.76 (1H, tt, 3JHF = 9.4 Hz, 4Jm = 2.3 Hz), 7.87 (1H, dd, V-
9.0 Hz, 4J= 2.4 Hz), 7.92 (1H, d, V- 2.2 Hz), 8.04 (1H, d, V= 9.0 Hz), about 10.1
(1H, broad S.-NHCO-).

WO 2005/000794 PCT/FI2004/000387
52
Example 75.
3-(2,3-Difluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(2,3-Difluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophraiyl)-
propionamide was prepared as described in Example lc starting from 2,3-difluoro-
phenol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide. The
crude product was purified twice by flash chromatography using first heptane/ethyl
acetate (8:2) and then dichloromethane as an eluent. Trituration in heptane, m.p. 68-
73 °C. *H NMR (300 MHz, DMSO-d6): 1.44 (3H, s), 2.53 (3H, s), 4.11 (1H, d, 2Jgm
= 9.9 Hz), 4.31 (1H, d, 2Jsm = 9.8 Hz), 6.28 (1H, s, -OH), 6.93 - 7.14 (3H, m), 7.86
(1H, dd, 3J= 8.9 Hz, 4J= 2.3 Hz), 7.91 (1H, d, V= 2.1 Hz), 8.03 (1H, d, V= 8.9
Hz), 10.15 (1H, s,-NHCO-).
Example 76.
3-(2,6-DiflucTOphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
3-(2,6-Difluorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example lc starting from 2,6-difluoro-
phenol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide. The
crude product was purified by flash chromatography using heptane/ethyl acetate as a
gradient eluent (9:1 - 7:3). !H NMR (400 MHz, DMSO-d*): 1.40 (3H, s), 2.53 (3H,
s), 4.16 (1H, d, 2Jsm = 10.0 Hz), 4.31 (1H, d, 2J-(m = 10.0 Hz), 6.18 (1H, broad s, -
OH), 7.06 - 7.12 (3H, m), 7.86 (1H, dd, 3J= 8.9 Hz, 4J= 2.3 Hz), 7.88 (1H, d, 4J=
2.3 Hz), 8.04 (1H, d, 3J = 8.8 Hz), 10.08 (1H, broad s, -NHCO-)
Example 77.
2-Hydroxy-2-me-(yl-N-(3-memyl-(nitrcphenyl)-3-(3-trifluoromethyl-
phenoxy)propionamide
2-Hydroxy-2-memyl-N-(3-memyl-4-mtrophenyl)-3-(3-trifluoromettiyl-
phenoxy)propionamide was prepared as described in Example lc starting from 3-
hydroxybenzotrifluoride and 2-methyloxirane-2-carbocyiic acid (3-methyl-4-
nitrophenyl)amide. The crude product was purified by flash chromatography using
heptane/ethyl acetate as a gradient eluent (9:1 - 5:5). Crystallization from

WO 2005/000794 PCT/FI2004/000387
53
CH2Cl2/EtOH/heptane, m.p. 84-87 °C. lH NMR (400 MHz, DMSO--fc): 1.45 (3H, s),
2.53 (3H, s), 4.07 (1H, d, 2Jgem = 9.8 Hz), 4.33 (1H, d, 2Jgem = 9.8 Hz), 6.25 (1H,
broad s, -OH), 7.23 (1H, s), 7.24 (1H, d, 3J= 6.7 Hz,), 7.28 (1H, d, 3J= 7.7 Hz,),
7.50 (1H, t, 3J= 8.3 Hz,), 7.88 (1H, dd, 3J= 8.9 Hz, 4J= 2.3 Hz), 7.92 (1H, d, V=
2.0 Hz), 8.03 (1H, d, 3J= 9.0 Hz), 10.15 (1H, broad s, -NHCO-).
Example 78.
3-(3,5-Dichlorophenoxy)-2-hydroxy-2-methyl-N-(3-me(hyl-4-nitrophenyl)-
propionamide
3-(3,5-Dichlorophenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example lc starting from 3,5-dichloro-
phenol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide. The
crude product was purified by flash chromatography using heptane/ethyl acetate as an
eluent (9:1). Crystallization from toluene, m.p. 141 -143 °C. 'H NMR (400 MHz,
DMSO-rftf): 1.42 (3H, s), 2.53 (3H, s), 4.05 (1H, d, 2Jgem = 10.1 Hz), 4.31 (1H, d,
2Jgem = 10.1 Hz), about 6.2 (1H, broad s, -OH), 7.04 (2H, distorted d, V = 1.9 Hz),
7.13 (1H, distorted t, 4J = 1.7 Hz), 7.87 (1H, d, 3J= 8.9 Hz), 7.92 (1H, s), 8.04 (1H,
d, V= 8.90 Hz), about 10.1 (1H, broad s, -NHCO-).
Example 79.
3-[4-(3-Chloropropyl)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide
a) 4-(3-Chloropropyl)phenol
3-(4-Hydroxyphenyl)-l-propanol (0.97 g, 0.006374 mol) and concentrated
HC1 (20 ml) were heated at 100 °C for 14 h. After being cooled, the reaction mixture
was poured into water and extracted with ethyl acetate. The extracts were washed
with water, dried and concentrated in vacuo to give a raw product. Purification by
flash chromatography (heptane/ethyl acetate 9:1) gave a pure product (0.98 g, 90%).
JH NMR (400 MHz, DMSO-4?): 1.95 (2H, quintet, 3J= 7.0 Hz), 2.59 (2H, t, 3J= 7.5
Hz), 3.58 (2H, t, 3J= 6.5 Hz), 6.67 (2H, d, 3J = 8.2 Hz), 6.99 (2H, d, 3J = 8.2 Hz),
9.15 (1H, s, -OH).

WO 2005/000794 PCT/FI2004/000387
54
b)3-[4-(3-Chloropropyl)phOTOxy]-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
3-[4-(3-Chloropropyl)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example lc starting from 4-(3-
chloropropyl)phenol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitro-
phenyl)amide. Purification twice by flash chromatography (first only dichloro-
methane and then heptane/ethyl acetate 9:1 as an eluent) gave a pure product, m.p.
110-112 °C. ]H NMR (400 MHz, DMSO--(): 1.43 (3H, s), 1.95 (2H, quintet, V= 7.0
Hz), 2.53 (3H, s), 2.62 (2H, t, 3J= 7.4 Hz), 3.58 (2H, t, V- 6.5 Hz), 3.95 (1H, d,
2Jgem = 9.6 Hz), 4.18 (1H, d, 2J#m = 9.5 Hz), 6.15 (1H, broad s, -OH), 6.84 (2H, d, 3J
= 8.5 Hz), 7.10 (2H, d, 3J= 8.4 Hz), 7.88 (1H, d, 3J= 9.1 Hz), 7.93 (1H, s), 8.03 (1H,
d, 3J= 9.0 Hz), 10.14 (1H, broad s, -NHCO-).
Example 80.
3-[4-(2-Oiloroethoxy)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)-propionamide
3-[4-(2-OJoroethoxy)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example lc starting from 4-(2-
chloroethoxy)phenol (H. K. A. C. Coolen et al., Recueil des Travaux Chimiques des
Pays-Bas 114(2) (1995) 65) and 2-methyl-oxirane-2-carbocylic acid (3-methyl-4-
nitrophenyl)amide. The crude product was purified by flash chromatography using
heptane/ethyl acetate (75:25) as an eluent, m.p. 131-133 °C. *H NMR (400 MHz,
DMSO-rf«j): 1.42 (3H, s), 2.53 (3H, s), 3.88-3.93 (3H, m), 4.14-4.18 (3H, m), about
6.2 (1H, broad s, -OH), 6.86 (4H, s), 7.88 (1H, d, 3J= 9.0 Hz), 7.92 (1H, s), 8.04
(1H, d, V= 9.0 Hz), about 10.1 (1H, broad s, -NHCO-).
Example 81.
2-Hydroxy-3-(4-memoxymethylphenoxy)-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
2-Hydroxy-3-(4-memoxymethylphenoxy)-2-methyl-N-(3-methyi-4-nitro-
phenyl)propionamide was prepared as described in Example lc starting from 4-
(methoxymethyl)phenol (J. M. Saa et al., J. Org. Chem. 53 (1988) 4263; D. R.
Dimmel and D. Shepard, J. Org. Chem. 47 (1982) 22) and 2-methyloxirane-2-

WO 2005/000794 PCT/FI2004/000387
55
carbocylic acid (3-methyl-4-nitrophenyl)amide. The crude product was purified by
using flash chromatography several times (dichloromethane/methanol 99:1,
heptane/ethyl acetate as a gradient eluent (9:1-7:3), dichloromethane/methanol
99.5:0.5). *H NMR (400 MHz, DMSO--fc): 1.43 (3H, s), 2.53 (3H, s), 3.22 (3H, s),
3.97 (1H, d, 2Jgem = 9.6 Hz), 4.20 (1H, d, 2Jgem = 9.5 Hz), 4.30 (2H, s), 6.19 (1H,
broad s, -OH), 6.89 (2H, d, 3J= 7.9 Hz), 7.20 (2H, d, 3J= 8.2 Hz), 7.88 (1H, d, 3J=
9.0 Hz), 7.93 (1H, s), 8.04 (1H, d, 3J= 9.0 Hz), 10.13 (1H, broad s, -NHCO-).
Example 82.
3-[4-(2-Fluoroethyl)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide
A solution of 2-hydroxy-3-[4-(2-hydroxyethylphenoxy]-2-methyl-N-(3-
methyl-4-nitrophenyl)propionainide (prepared in Example 20,300 mg, 0.0008012
mol) in dry CH2C12 (3 ml) was treated with Deoxo-Fluor® (195 mg, 0.0008813 mol)
in dry CH2CI2 (1 ml) at -15 to -10 °C. The solution was stirred for 2 h at 0 °C and
then for 3 days at room temperature. The saturated NaHCCh solution was added and
the mixture was extracted with dichloromethane. The combined extracts were
washed with water, dried over Na2SC)-4, filtered, and evaporated in vacuo. The crude
product was purified by flash chromatography using dichloromethane as an eluent.
Crystallization from toluene afforded the desired compound as pure crystals: m.p.
102-105 °C. 'H NMR (400 MHz, DMSO-d6): 1.43 (3H, s), 2.53 (3H, s), 2.88 (2H, dt,
3JHF = 24.4 Hz, 3J= 6.4 Hz), 3.95 (1H, d, 2Jgem = 9.8 Hz), 4.18 (1H, d, 2Jsm = 9.5
Hz), 4.56 (2H, dt, 2Jm = 47.4 Hz, V= 6.4 Hz), 6.18 (1H, broad s, -OH), 6.85 (2H, d,
V= 8.5 Hz), 7.15 (2H, d, V= 8.4 Hz), 7.88 (1H, d, 3J= 9.0 Hz), 7.93 (1H, s), 8.03
(1H, d, V= 9.0 Hz), 10.13 (1H, broad s, -NHCO-).
Example 83.
3-(4-Fluoromethylphenoxy)-2-hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
A solution of 2-hydroxy-3-(4-hydroxymethylphenoxy)-2-methyl-NK3-
methyl-4-nitrophenyl)propionamide (prepared in Example 70,950 mg, 0.002636
mol) in dry CH2C12 (6.5 ml) was treated with Deoxo-FluorR (875 mg, 0.003954 mol)
in CH2C12 (3 ml) at -76 °C. The solution was stirred at -10 °C for 3 hours. The
saturated NaHCO3 solution was added and the mixture was extracted with

WO 2005/000794 PCT/FI2004/000387
56
dichloromethane. The combined extracts were washed with water, dried over
Na2SO4, filtered, and evaporated in vacuo. The crude product was purified by flash
chromatography using heptane/ethyl acetate as a gradient eluent (9:1-5:5).
Crystallization from dichloromethane/heptane gave the desired compound. *H NMR
(400 MHz, DMSO-Jtf): 1.44 (3H, s), 2.53 (3H, s), 4.00 (1H, d, 2Jgem = 9.7 Hzj, 4.24
(1H, d, 2Jgem = 9.6 Hz), 5.30 (2H, d, 2JHF = 48.6 Hz), 6.21 (1H, s, -OH), 6.95 (2H, d,
V= 8.4 Hz), 7.34 (2H, d, 3J= 8.6 Hz), 7.84 (1H, dd, 3J= 9.0 Hz, V= 2.0 Hz), 7.93
(1H, broad s), 8.03 (1H, d, 3J= 9.0 Hz), 10.14 (1H, s, -NHCO-).
Example 84.
3-[4-(2-Bromoethyl)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide
a) 4-(2-Bromoethyl)phenol
(4-Hydroxyphenethyl) alcohol (1.50 g, 0.01086 mol) and 48 wt. % hydro-
bromic acid (10 ml) were heated at 100 °C for 1.5 h. After being cooled, the reaction
mixture was poured into water and extracted with ethyl acetate. The extracts were
washed with water, dried and concentrated in vacuo to give a raw product. Purifi-
cation by flash chromatography (heptane/ethyl acetate 9:1) gave a pure product (2.01
g, 92%). lH NMR (400 MHz, DMSO-d6): 2.99 (2H, t, 3J= 7.4 Hz), 3.63 (2H, t, 3J=
7.4 Hz), 6.68 (2H, d, 3J = 8.5 Hz), 7.05 (2H, d, V = 8.3 Hz), 9.24 (1H, s, -OH).
b) 3-[4-(2-Bromoethyl)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide
3-[4-(2-Bromoethyl)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example lc starting from 4-(2-
bromoethyl)phenol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)-
amide. Purification by flash chromatography on silica gel (dichloromethane/methanol
99:1 or toluene/methanol 99.5:0.5 gave an impure product. The final purification was
made by preparative HPLC. *H NMR (400 MHz, CDC13): 1.59 (3H, s), 2.63 (3H, s),
3.10 (2H, t, V= 7.5 Hz), about 3.5 (-OH), 3.52 (2H, t, 3J= 7.4 Hz), 3.98 (1H, d, 2Jsm
= 9.0 Hz), 4.44 (1H, d, Vj» « 9.0 Hz), 6.87 (2H, d, V= 8.6 Hz), 7.13 (2H, d, 3J=
8.6 Hz), 7.57 (1H, dd, 3J= 8.9 Hz, 4J= 2.3 Hz), 7.65 (1H, d, 4J= 2.2 Hz), 8.06 (1H,
d, V= 8.9 H-(s), 9.00 (1H, s, -NHCO-).

WO 2005/000794 PCT/FI2004/000387
57
Example 85.
2-Hydroxy-3-[4-(2-iodoethyl)phenoxy]-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide
a) 4-(2-Iodoethyl)phenol
Triphenyphosphine (1.57 g, 0.006 mol) and imidazole (0.41 g, 0.006 mol)
were added to dry dichloromethane (20 ml). When the imidazole was in solution
iodine (1.52 g, 0.006 mol) was added. After precipitation of the imidazole hydro-
iodide (4-hydroxyphenethyl) alcohol (0.69 g, 0.005 mol) was added. The mixture was
stirred at room temperature for 4 h. Then water was added and the mixture was
extracted with dichloromethane. The extracts were washed with water, dried and
concentrated in vacuo to give a raw product. Purification by flash chromatography
(heptane/ethyl acetate as a gradient eluent 9:1 - 6:4) gave a pure product *H NMR
(400 MHz, DMSO-dtf): 2.99 (2H, t, V= 7.6 Hz), 3.38 (2H, t, 3J= 7.6 Hz), 6.68 (2H,
d, 3J = 8.5 Hz), 7.03 (2H, d, 3J = 8.5 Hz), 9.24 (1H, s, -OH).
b)2-Hydroxy-3-[4-(2-iodoethyl)phenoxy]-2-methyl-N-(3-methyl-4-mtro-
phenyl)propionamide
2-Hydroxy-3-[4-(2-iodoethyl)phenoxy]-2-methyl-N-(3-methyl-4-nitrophenyl)-
propionamide was prepared as described in Example lc starting from 4-(2-iodo-
ethyl)phenol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-nitrophenyl)amide.
Purification by flash chromatography on silica gel (heptane/ethyl acetate as a gradient
eluent 9:1 - 6:4) gave an impure product. The final purification was made by
preparative HPLC. JH NMR (400 MHz, DMSO-d*): 1.43 (3H, s), 2.53 (3H, s), 3.03
(2H, t, 3J= 7.4 Hz), 3.40 (2H, t, 3J= 7.4 Hz), 3.96 (1H, d, 2Jgem = 9.6 Hz), 4.19 (1H,
d, 2Jgem = 9.6 Hz), 6.17 (1H, s, -OH), 6.85 (2H, d, 3J= 8.6 Hz), 7.14 (2H, d, V= 8.6
Hz), 7.88 (1H, dd, V- 9.0 Hz, 4J= 2.2 Hz), 7.93 (1H, d, V= 2.0 Hz), 8.03 (1H, d, 3J
== 9.0 Hz), 10.13 (1H, s, -NHCO-).
Example 86.
3-[4-(2-Bromoethoxy)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide

WO 2005/000794 PCT/FI2004/000387
58
a) 4-(2-Bromoethoxy)phenol
Potassium carbonate (7.53 g, 0.05448 mol) was added to the acetone solution
(50 ml) of hydroquinone (2.00 g, 0.01816 mol) and 1,2-dibromoethane (3.39 g,
0.01805 mol). The mixture was heated at reflux for 6 h under nitrogen. The resulting
mixture was filtered, water was added and pH was adjusted to 2-3. The mixture was
extracted with ethyl acetate. The extracts were washed with water, dried over
anhydrous NaaSCU, filtered and evaporated. The crude product was purified by flash
chromatography on silica gel, using heptane/ethyl acetate as a gradient eluent (95:5 -
70:30) to afford the pure desired compound as white crystals. *H NMR (400 MHz,
DMSO-4$): 3.74 (2H, t, V- 5.5 Hz), 4.19 (2H, t, V= 5.5 Hz), 6.67 (2H, d, V= 8.9
Hz), 6.78 (2H, d, V= 8.9 Hz), 8.95 (1H, s, -OH).
b)3-[4-(2-Bromoethoxy)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)propionamide
3-[4-(2-Bromoemoxy)phenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-nitro-
phenyl)propionamide was prepared as described in Example lc starting from 4-(2-
bromoethoxy)phenol and 2-methyl-oxirane-2-carbocylic acid (3-methyl-4-nitro-
phenyl)amide. The crude product was purified by flash chromatography on silica gel,
using heptane/ethyl acetate as a gradient eluent (9:1 - 6:4). The desired compound
was crystallized from dichloromethane, m.p. 135-138 °C. *H NMR (400 MHz,
DMSO-rf*): 1-42 (3H, s), 2.53 (3H, s), 3.75 (2H, t, V« 5.5 Hz), 3.92 (1H, d, V-( =
9.6 Hz), 4.15 (1H, d, tjge,, = 9.5 Hz), 4.23 (2H, t, V= 5.4 Hz), 6.16 (1H, broad s, -
OH), 6.86 (4H, s), 7.88 (1H, dd, V= 9.0 Hz, 4J= 2.2 Hz), 7.92 (1H, d, V- 1.7 Hz),
8.04 (1H, d, V= 8.9 Hz), 10.12 (1H, broad s, -NHCO-).
Example 87.
3-[4-(2-CUoroemyl)-3-fluorophenoxy]-2-hydK)xy-2-memyl-N-(3-methyl-4-
nitrophenyl)-propionamide
a) 3-Fluoro-4-(2-hydroxyethyl)phenol
Boi-(e-tetrahydrofuran complex (1.0 M solution in THF, 22 ml, 0.02200
mol) was added dropwise to the solution of (2-fluoro-4-hydroxyphenyl)acetic acid (P.
C. Belanger et al. EP 106565 Ql, 2.27 g, 0.01145 mol) in dry THF (40 ml) under

WO 2005/000794 PCT/FI2004/000387
59
nitrogen at -10 °C, and the resulting solution was stirred for 2 h at -10 °C. Water was
added and the product was extracted into ethyl acetate. The combined extracts were
washed with water, dried and evaporated in vacuo to give the product. 'H NMR (400
MHz, DMSO-40: 2.62 (2H, t, 3J= 7.2 Hz), 3.50 (2H, m), 4.63 (1H, t, 3J= 5.4 Hz, -
CH2OH), 6.47-6.53 (2H, m), 7.06 (1H, t, 3Jm = %F = 8.5 Hz), 9.60 (1H, s, ArOH).
b) 4-(2-Chloroethyl)-3-fluorophenol
4-(2-Chloroethyl)-3-fluorophenol was prepared as described in Example 74a
starting from 3-fluoro-4-(2-hydroxyethyl)phenol. The crude product was purified by
flash chromatography using heptane/ethyl acetate as an eluent (85:15). 'H NMR (400
MHz, DMSO-40: 2.93 (2H, t, 3J= 7.1 Hz), 3.74 (2H, t, 3J= 7.1 Hz), 6.51-6.57 (2H,
m), 7.13 (1H, t, 3Jm = 4JHF = 8.1 Hz), 9.75 (1H, s, ArOH).
c)3-[4-(2-Chloroethyl)-3-fluorophenoxy]-2-hydroxy-2-methyl-N-(3-methyl-
4-nitrophenyl)propionamide
3-[4-(2-Chloroethyl)-3-fluorophenoxy]-2-hydroxy-2-methyl-N-(3-methyl-4-
nitrophenyl)-propionamide was prepared as described in Example lc starting from 4-
(2-chloroethyl)-3-fluorophenol and 2-methyloxirane-2-carbocylic acid (3-methyl-4-
nitrophenyl)amide. The crude product was purified by flash chromatography using
dichloromethane as an eluent. The product was crystallized from dichloromethane-
/heptane: m.p. 77-79 °C. *H NMR (400 MHz, TMSO-d6): 1.43 (3H, s), 2.53 (3H, s),
2.97 (2H, t, 3J= 6.9 Hz), 3.76 (2H, t, 3J= 7.0 Hz), 3.98 (1H, d, V-(, = 9.8 Hz), 4.23
(1H, d, 2Jgem = 9.7 Hz), about 6.2 (1H, broad s, -OH), 6.73 (1H, dd, V= 8.5 Hz, 4J=
2.4Hz), 6.80 (1H, dd, 3JHF= 12.1 Hz, 4JHH=2.5 HZ), 7.24 (1H, t, 3JHH=4JHF= 8.8
Hz), 7.87 (1H, dd, V= 9.0 Hz, 4J= 2.3 Hz),7.92 (1H, d, 4J= 2.0 Hz), 8.03 (1H, d, 3J
= 9.0 Hz), about 10.1 (1H, broad s, -NHCO-).
Example 88.
3-(4-Cyanophenoxy)-N-(3-emyl-4-nitrophenyl)-2-hydroxy-2-methylpropion-
amide
a)N-(3-Ethyl-4-nitrophenyl)-2-methylacrylamide

WO 2005/000794 PCT/FI2004/000387
60
N-(3-Ethyl-4-nitrophenyl)-2-methylacrylamide was prepared as described in
Example la starting from 3-ethyl-4-nitrophenylamine (W. Pfleiderer et al. US
2002/0146737 Al) and methacryloyl chloride. The crude product was purified by
flash chromatography using heptane/ethyl acetate (9:1) as an eluent. *H NMR (400
MHz, DMSO-4$): 1.22 (3H, t, 3J= 7.4 Hz), 1.97 (3H, s), 2.87 (2H, q, 3J= 7.4 Hz),
5.62 (1H, s), 5.88 (1H, s), 7.81 (1H, dd, 3J= 8.9 Hz, V= 2.3 Hz), 7.83 (1H, d, 4J=
2.2 Hz), 8.00 (1H, d, 3J= 8.8 Hz), 10.21 (1H, s, -NHCO-).
b) 2-Methyloxirane-2-carboxylic acid (3-ethyl-4-nitrophenyl)amide
3-Chloroperoxybenzoic acid (14.71 g, 0.08524 mol) was added in portions to
the refluxing solution of N-(3-ethyl-4-nitrophenyl)-2-methylacrylamide (6.68 g,
0.02852 mol) and 2,6-di-terr-butyl-4-methylphenol (149 mg) in dichloromethane
(180 ml). After refluxing for 5 h the reaction mixture was allowed to cool to room
temperature. The precipitated 3-chlorobenzoic acid was filtered, and the filtrate was
extracted three times with 1M Na2CO3 and water. The organic phase was dried over
Na2SO4, filtered and evaporated. The crude product was purified by flash chromato-
graphy using dichloromethane as an eluent. *H NMR (400 MHz, DMSO-J6): 1.20
(3H, t, 3J= 7.4 Hz), 1.55 (3H, s), 2.84 (2H, q, 3J= 7.4 Hz), 2.99 (1H, d, 2Jgan = 5.1
Hz), 3.06 (1H, d, 2Jiem = 5.1 Hz), 7.81 (1H, dd, 3J= 9.0 Hz, V- 2.3 Hz), 7.85 (1H, d,
V= 2.2 Hz), 7.97 (1H, d, 3J= 9.0 Hz), 9.88 (1H, s, -NHCO-).
c)3-(4-Cyanophenoxy)-N-(3-ethyl-4-nitrophenyl)-2-hydroxy-2-methyl-
propionamide
3-(4-Cyanophenoxy)-N-(3-ethyl-4-nitrophenyl)-2-hydroxy-2-methylpropion-
amide was prepared as described in Example lc starting from 4-cyanophenol and 2-
methyloxirane-2-carbocylic acid (3-ethyl-4-nitrophenyl)amide. The crude product
was purified by flash chromatography using heptane/ethyl acetate as a gradient eluent
(9:1- 6:4). *H NMR (400 MHz, DMSO-d6): 1.21 (3H, t, 3J= 7.4 Hz), 1.45 (3H, s),
2.86 (2H, q, 3J= 7.5 Hz), 4.09 (1H, d, 'j-( = 9.9 Hz), 4.33 (1H, d, 2J-( = 9.8 Hz),
6.26 (1H, broad s, -OH), 7.11 (2H, d, V= 8.8 Hz), 7.74 (2H, d, 3J= 8.7 Hz), 7.89
(1H, d, 3J= 9.1 Hz), 7.94 (1H, s), 7.98 (1H, d, 3J= 8.9 Hz), 10.17 (1H, broad s, -
NHCO-).

WO 2005/000794 PCT/FI2004/000387
61
Example 89.
3-(4-Cyano-3-fluorophenoxy)-N-(3-ethyl-4-nitrophenyl)-2-hydroxy-2-methyl-
propionamide
3-(4-Cyano-3-fluorophenoxy)-N-(3-ethyl-4-nitrophenyl)-2-hydroxy-2-
methylpropionamide was prepared as described in Example lc starting from 2-
fluoro-4-hydroxybenzonitrile and 2-methyl-oxirane-2-carbocylic acid (3-ethyl-4-
nitrophenyl)amide. The crude product was purified twice by flash chromatography
using heptane/ethyl acetate as a gradient eluent and the final purification was made
by preparative HPLC. 'H NMR (400 MHz, DMSO-d6): 1.21 (3H, t, V= 7.4 Hz),
1.44 (3H, s), 2.86 (2H, q, V= 7.5 Hz), 4.12 (1H, d, 2Jgem = 10.0 Hz), 4.38 (1H, d,
2Jgem = 10.0 Hz), 6.30 (1H, broad s, -OH), 6.96 (1H, dd, 3J= 8.7 Hz, V= 2.2 Hz),
7.18 (1H, dd, 3JHF= 11.8 Hz, %/ = 2.3 Hz), 7.80 (1H, t, 3JHH = 4JHF= 8.3 Hz), 7.89
(1H, dd, 3J= 8.9 Hz, 4J= 2.2 Hz), 7.95 (1H, d, 4J= 2.3 Hz), 7.98 (1H, d, 3J= 9.0
Hz), 10.18 (1H, s,-NHCO-).
Example 90.
2-Hydroxy-2-memyl-N-(3-memyl-(mtrophenyl)-3-(3-methyl-4-nitrophenyl-
amino)propionamide
2-Hydroxy-2-methyl-N-(3-methyl-4-nitrophenyl)-3-(3-methyl-4-nitrophenyl-
amino)propionamide was prepared as described in Example 52 starting from 1,2-
epoxy-2-memyl-N-[3-methyl-4-nitrophenyl]-2-propanamide. 'H-NMR (400 MHz,
DMSO-de): 1.62 (3H, s), 2.54 (3H, s), 2.60 (3H, s), 3,41 (1H, dd, J = 13.6 Hz, J = 6.0
Hz), 3.83 (1H, dd, J = 13.6 Hz, J = 6.9 Hz), 4.81 (1H, t, J = 6.3 Hz), 6.46 (1H, d, 2.1
Hz), 6.51 (1H, dd, J = 9.1 Hz, J = 2.5 Hz), 7.54 (1H, dd, J = 8.9 Hz, J = 2.2 Hz), 7.59
(1H, d, J = 1.8 Hz), 7.97 (1H, d, J = 9.0 Hz), 8.02 (1H, d, J = 8.9 Hz), 8.96 (1H, s).
Example 91.
3-[4-(3,3-dimemylureido)-3-fluorophenoxy]-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl)propionamide
a) 3-(2-fluoro-4-hydroxyphenyl)-1,1 -dimethylurea
4-Amino-3-fluorophenol (0.47 g; 3.0 mmol) was dissolved in 15 ml of dry
THF under nitrogen, cooled to 0°C and N,N'-dimethylcarbamyl chloride (0.28 ml;

WO 2005/000794 PCT/FI2004/000387
62
3.0 mmol) was added dropwise. The reaction was allowed to heat to room
temperature and then refluxed for 4 hours. The reaction was cooled again to 0°C and
0.2 ml of water was added and the reaction filtered. The mother liquor was
evaporated, dissolved in 25 ml of EtOAc, washed with 10 ml of 1M Na2CC)-3,10 ml
of water and dried over Na2SC)-4. The product was purified by chromatography
(EtOAc:toluene 1:1). lH NMR (400 MHz, DMSO-d*): 2.88 (6H, s), 6.48-6.58 (2H,
m), 7.02-7.10 (1H, m), 9.65 (1H, s).
b)3-[4-(3,3-dimethylureido)-3-fluorophenoxy]-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl)propionamide
3-[4-(3,3-dimethylureido)-3-fluorophenoxy]-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl)propionamide was prepared as described in Example 1 from 3-
(2-fluoro-4-hydroxyphenyl)-l,l-dimethylurea and l,2-epoxy-2-methyl-N-[3-methyl-
4-nitrophenyl]-2-propanamide. 'H NMR (400 MHz, DMSO-de): 1.42 (3H, s), 2.53
(3H, s), 2.88 (6H, s), 3.96 (1H, d, J = 9.7 Hz), 4.21 (1H, d, J = 9.7 Hz), 6.25 (1H, s),
6.68 (1H, dd, J = 8.8 Hz, J = 2.4 Hz), 6.81 (1H, dd, J = 12.3 Hz, J = 2.7 Hz), 7.10-
7.30 (1H, m), 7.86 (1H, s), 7.88 (1H, dd, J = 9.1 Hz, J = 2.2 Hz), 7.93 (1H, d, J = 1.9
Hz), 8.04 (1H, d, J = 9.0 Hz), 10.15 (1H, s).
Example 92.
3-(3-Fluoro-4-methanesulfonylaminophenoxy]-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl)propionamide
a) N-(2-Fluoro-4-hydroxyphenyl)methanesulfonainide
4-Amino-3-fluorophenol (0.254g; 2.0 mmol) was dissolved in 10 ml of dry
pyridine under nitrogen and cooled to 0°C. Methanesulfonyl chloride (0.17 ml; 2.1
mmol) was added dropwise and stirred for three days at room temperature. The
reaction was evaporated, 25 ml of toluene added and evaporated again. Toluene
evaporation was repeated. Residue was dissolved in 25 ml of EtOAc, washed with 20
ml of water and evaporated to dryness to give red-brown solid N-(2-fluoro-4-
hydroxyphenyl)methanesulfonainide. 'H NMR (400 MHz, DMSO-dts): 2.93 (3H, s),
6.56-6.66 (2H, m), 7.14 (1H, t, J = 9.0 Hz), 9.17 (1H, s), 9.98 (1H, s).

WO 2005/000794 PCT/FI2004/000387
63
b) 3-(3-Fluoro-4-methanesulfonylaminophenoxy]-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl)propionamide
3-(3-Fluoro-4-methanesulfonylaminophenoxy]-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl)propionainide was prepared as in Example 1 starting from 4-
amino-2-fluorophenol and l-(-epoxy-2-methyl-N-[3-methyl-4-nitrophenyl]-2-
propanamide. 'H NMR (400 MHz, DMSO-de): 1.43 (3H, s), 2.53 (3H, s), 2.92 (3H,
s), 3.99 (1H, d, J = 9.8 Hz), 4.24 (1H, d, J = 9.8 Hz), 6.25 (1H, s), 6.76 (1H, dd, J =
8.9 Hz, J = 2.0 Hz), 6.93 (1H, dd, J = 12.1 Hz, J = 2.7 Hz), 7.23 (1H, t, J = 9.1 Hz),
7.88 (1H, dd, J = 9.0 Hz, J = 2.2 Hz), 7.93 (1H, d, J = 1.9 Hz), 8.04 (1H, d, J = 9.0
Hz), 9.29 (1H, s), 10.16 (1H, s).
Example 93.
3-[4-(2-ammoacetylamino)-3-fluorophenoxy]-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl) propionamide
a)[(2-Fluoro-(hydroxyphenylcarbamoyl)carbamicacid-terf-butylester
tert-Butoxycarbonylamino acetic acid (= Boc-glycine) (0.256 g; 2.0 mmol)
was dissolved in 10 ml of CH2C12 under nitrogen and cooled to 0°C. DCC (0.412 g;
2.0 mmol) was added and allowed to heat to room temperature. 4-Amino-3-fluoro-
phenol (0.350 g; 2.0 mmol) was added in 10 ml of CH2CI2 followed with 5 ml of
THF. The reaction was stirred for 2 hours at room temperature, refluxed for 2 hours
and stirred overnight at room temperature. The reaction was evaporated, dissolved in
30 ml of EtOAc and some heptane was added in order to precipitate out the residues
(DHU) formed from DCC. The precipitate was filtered and washed with heptane. A
mother liquor was evaporated, dissolved in 10 ml of EtOAc and 2 ml of toluene was
added dropwise to give a precipitation. After filtration the filtrate was evaporated to
give [(2-fluoro-(hydroxyphenylcarbamoyl)carbamicacid-/err-butylester. 'H-NMR
(400 MHz, DMSO-de): 1.39 (9H, s), 3.71 (2H, d, J = 6.0 Hz), 6.52-6.65 (2H, m),
7.00-7.07 (1H, m), 7.41-7.49 (1H, m), 9.34 (1H, s), 9.74 (1H, s).
b) ({2-Fluoro-4-[2-hydroxy-2-(3-memyl-4-nitrophenylc»rbamoyl}methyl)-
carbamicacid-tert-butylester

WO 2005/000794 PCT/FI2004/000387
64
( {2-Fluoro-4-[2-hydroxy-2-(3-methyl-4-nitrophenylcarbamoyl} methyl)-
carbamicacid-tert-butylester was prepared as described in Example 1 starting from
[(2-fluoro-4-hydroxyphenylcaibamoyl)-carbamicacid-tert-butylester and 1,2-epoxy-
2-methyl-N-[3-mettiyl-4-nitrophenyl]-2-propanamide. 'H-NMR (400 MHz, DMSO-
dfi): 1.39 (9H, s), 1.43 (3H, s), 2.53 (3H, s), 3.73 (2H, d, J = 5.4 Hz), 3.97 (1H, d, J =
9.8 Hz), 4.22 (1H, d, J = 9.8 Hz), 6.24 (1H, s), 6.74 (1H, d, J = 9.3 Hz), 6.89 (1H, d, J
= 12.0 Hz), 7.00-7.10 (1H, m), 7.60 (1H, t, J = 8.9 Hz), 7.88 (1H, d, J = 9.0 Hz), 7.93
(1H, s), 8.04 (1H, d, J = 9.0 Hz), 9.46 (1H, s), 10.15 (1H, s).
c)3-[4-(2-aininoacetylamino)-3-fluorophenoxy]-2-hydroxy-2-methyl-N-(3-
methyl-4-nitrophenyl)-propionamide
({2-Fluoro-4-[2-hydroxy-2-(3-methyl-4-nitropb.enylcarbamoyl}methyl)-
carbamicacid-terf-butylester (0.160 g; 0.3 mmol) was dissolved in 5 ml of CH2CI2
under nitrogen and cooled to 0°C. Trifluoroaceticacid (0.5 ml) was added dropwise
and the reaction allowed to warm to room temperature followed with stirring for 2
hours at room temperature. The reaction was evaporated to dryness, the residue was
dissolved in 25 ml of EtOAc and washed with 10 ml of water. Toluene (25 ml) was
added and evaporated to dryness carefully to give 3-[4-(2-arninoacetylamino)-3-
£luorophenoxy]-2-hydroxy-2-memyl-N-(3-memyl-4-nitrophenyl)propionamide. JH-
NMR (400 MHz, DMSO-d-s): 1.43 (3H, s), 2.53 (3H, s), 3.75-3.85 (2H, m), 3.98 (1H,
d, J = 9.1 Hz), 4.24 (1H, d, J = 9.3 Hz), 6.25 (1H, s), 6.78 (1H, d, J = 9.0 Hz), 6.95
(1H, d, J = 13.0 Hz), 7.60-7.72 (1H, m), 7.88 (1H, d, J = 8.8 Hz), 7.93 (1H, s), 8.00-
8.15 (4H, m), 10.05 (1H, s), 10.12 (1H, s).

WO 2005/000794 PCT/FI2004/000387
65
Claims
1. Compounds of formula (I)

wherein
R1 is (C1-C7)alkyl, hydroxy(C1-C7)alkyl or -(CH2)n-CHO, wherein n is 0-6;
R.2 is nitro, cyano or halogen;
R3 is hydrogen, (C1-C7)alkyl or halo(C1-C7)alkyl;
R4 is hydrogen, (C1-C7)alkyl, COR10 or SO2R13;
XisOorNH;
A is a group selected from:

wherein R5, Re, R7, Rg and R9 are independently hydrogen, halogen, nitro, cyano,
(C1-C7)alkyl, halo(C1-C7)alkyl, cyano(C1-C7)alkyl, amino, mono- or di(C1-C7)alkyl-
amino, amino(C1-C7)alkyl, hydroxy(C1-C7)alkyl, (C1-C7)alkoxy(C1-C7)alkyl,
-NHCOR10, -N(CORio)2, -CORH, -OR12, -OSO2R13, -SO2R14, -NHSO2R13 or-SR15 or
an imide ring; or R5 and R& Re and R7, R7 and Rg, or Rg and R9 form, together with any
of the ring atom(s) to which they are attached, a condensed 5 to 7 membered aliphatic or
aromatic carbocyclic ring or a condensed 5 to 7 membered heterocyclic ring containing
1 to 3 heteroatom(s) selected from N, O and S;
R10 and Rn are independently (C1-C7)alkyl, (C2-C7)alkenyl, halo(C1-C7)alkyl,
amino(C1-C7)alkyl, mono- or di(C1-C7)alkylamino(C1-C7)alkyl, (C6-C10)aryl, -N(Ri6)-2
or -ORn;

WO 2005/000794 PCT/F12004/000387
66
R12 and RJ5 are independently hydrogen, (C1-C7)alkyl, (C2-C7)alkenyl,
halo(C1-C7)alkyl, amino(d-C7)alkyl, mono- or di(CrC7)alkylamino(C1-C7)alkyl,
(C6-Ci0)aryl, -COR18;
R13 and RM are independently (C1-C7)alkyl or (C2-C7)alkenyl, halo(Ci-
C7)alkyl or (C6-C10)aryl;
Ri6 and Rp are independently hydrogen, (C1-C7)alkyl, (C2-C7)alkenyl,
halo(C1-C7)alkyl, amino(C1-C7)alkyl or (C6-C10)aryl;
Ris is (C1-C7)alkyl, (C2-C7)alkenyl, halo(C1-C7)alkyl or (C6-C10)aryl;
R19 and R20 are independently hydrogen, halogen, (C1-C7)alkyl or (C2-
C7)alkenyl;
and wherein each aryl or ring residue defined above may be substituted;
and pharmaceutically acceptable salts and esters thereof.
2. A compound according to claim 1, wherein R4 is hydrogen and R3 is
methyl.
3. A compound according to claim 1 or 2, wherein X in O.
4. A compound according to any of claim 1 to 3, wherein R1 is methyl or
hydroxymethyl and R2 is nitro or cyano.
5. A compound according to any of claims 1 to 4, wherein R5, R$, R7, Rg and
R9 are independently hydrogen, halogen, nitro, cyano, (C1-C7)alkyl, (C1-C7)alkoxy,
halo(C1-C7)alkyl, hydroxy(C1-C7)alkyl or -NHCOR10, wherein R10 is (C1-C7)alkyl,
halo(C1-C7)alkyl, hydroxy or (C1-C7)alkoxy.
6. A compound according to claim S, wherein at least one of R5, R$, R7, Rg
and Rg is a halogen.
7. A compound according to claim 6, wherein at least two of R5, R-(, R7, Rg
and R9 are selected from a group consisting of halogen, cyano and acetamido.
8. A pharmaceutical composition comprising a compound of formula (I)
together with a pharmaceutically acceptable carrier.

WO 2005/000794 PCT/FI2004/000387
67
9. A method of hormonal therapy, comprising administering to a subject in
need thereof a therapeutically effective amount of a compound of formula (I).
10. A method for the treatment or prevention of androgen receptor dependent
conditions, comprising administering to a subject in need thereof a therapeutically
effective amount of a compound of formula (I).
11. A method according to claim 9 or 10, comprising administering a
therapeutically effective amount of a compound of formula (I) orally.

Compounds of formula (I) wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g. in the treatment or prevention of male hypogonadism and age-related conditions such as andropause.